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Abstract 
Therapy and mechanism of Mendelian eye diseases 
Yi-Ting Tsai 
 
Retinal degenerative diseases cause varying degrees of irreversible vision loss in 
millions of people worldwide. Common to all retinal degenerative diseases is the 
malfunction or demise of photoreceptor cells or its supportive cells, retinal pigment 
epithelium cell in the retina. A considerable part of these diseases were resulted from the 
inherited mutations of essential genes expressed in these retinal cells. The understanding 
of pathologic mechanism as well as developing of therapeutic treatment for these 
diseases were discussed in this study. 
A cutting-edge therapeutic genome editing technology is studied in the first part 
of study. This technology was invented to treat retinitis pigmentosa via engineered 
nucleases, which has great clinical potential for autosomal dominant genetic disorders 
that were previously irreparable by conventional gene therapy interventions. Though 
customizable gene editing tools can be engineered to target specific mutation sites, 
however it is too daunting for diseases like retinitis pigmentosa, a progressive retinal 
degenerative condition associated with more than 150 mutations in the rhodopsin gene 
alone. Here in this study, we present an “ablate-and-replace” combination strategy that 
1) destroys expression of the endogenous gene by CRISPR/Cas9 in a mutation-
independent manner, and 2) enables expression of wild-type protein through exogenous 
cDNA. As proof of concept, we show that our CRISPR-based therapeutic machinery 
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efficiently ablates mRho in vivo, and when combined with gene replacement therapy, 
ameliorates rod photoreceptor degeneration and improves visual function in two 
genetically distinct autosomal dominant retinitis pigmentosa animal models. This 
mutation-independent, ablate-and-replace strategy represents the first 
electrophysiological recovery by a CRISPR-mediated therapy in an autosomal dominant 
disorder and it offers a clinically relevant, universal strategy to overcome allelic 
heterogeneity in debilitating inherited conditions. 
For the second part of the study, gene editing technology was used to study the 
pathogenesis of Doyne honey comb dystrophy, another Mendelian disease with extensive 
similarities to age-related macular degeneration. This monogenic disorder is caused by a 
unique point mutation on an extracellular matrix protein EFEMP1, expressed by retinal 
pigment epithelium cell. To precisely gauge the physiological effect resulted from this 
mutation, CRISPR-mediated gene correction was used to create isogeneic cell pairs from 
patient donated tissue-derived stem cells. These stem cells were differentiated into 
retinal pigment epithelium cell before analysis. We found unfolded protein response and 
immune response were not involved in the pathogenesis, which contradicts existing 
theories. Via proteomics analysis, we found expression level of a cholesterol catabolic 
enzyme was affected by the EFEMP1 mutation while those proteins controlling the 
cholesterol transport remains constant. This result provides supportive evidence to 
explain the aberrant intracellular accumulation of cholesterol found in patient retinal 
pigment epithelium cells. This imbalance in lipid homeostasis also suggests Doyne honey 
comb dystrophy is a retinal pigment epithelium cell-autonomous disease. 
i 
 
Table of Contents 
 
LIST OF FIGURES ............................................................................................................... iv  
ACKNOWLEDGEMENTS ................................................................................................... vii 
 
CHAPTER 1: BACKGROUND OF OPHTHALMOLOGY, DISEASES AND POTENTIAL     . 
TREATMENTS ...............................................................................................................  001 
I. THE EYE AND THE RETINA ……………......................................................  001 
 BRIEF OVERVIEW OF THE EYE AND THE RETINA ...........................  001 
 PHOTOTRANSDUCTION CASCADE .................................................  004 
II. EYE DISEASES .......................................................................................  011 
 RETINAL DEGENERATION ............................................................... 011 
 RETINITIS PIGMENTOSA ................................................................  012 
 DOYNE HONEY COMB DYSTROPHY ...............................................  017 
III. THERAPY FOR GENETIC DISEASES .......................................................  021 
 BRIEF OVERVIEW OF CURRENT EXPERIMENTAL THERAPIES ........  021 
 GENE THERAPY ...............................................................................  025 
 GENE EDITING ................................................................................  026 
 ADENO-ASSOCIATED VIRAL VECTORS ...........................................  031 
 GENE THERAPY CLINICAL TRIALS ...................................................  039 
 
CHAPTER 2: ESTABLISHMENT OF CRISPR-MEDIATED GENE ABLATION .....................  041 
ii 
 
I. INTRODUCTION ....................................................................................  041 
II. RESULT .................................................................................................  045 
III. DISCUSSION .........................................................................................  050 
 
CHAPTER 3: ESTABLISHMENT OF AAV VECTORS AND SUBRETINAL INJECTION OF GENE 
THERAPY VECTORS ......................................................................................................  051 
I. INTRODUCTION ....................................................................................  051 
II. RESULT .................................................................................................  052 
III. DISCUSSION .........................................................................................  065 
 
CHAPTER 4: TEST OF ABLATE-AND-REPLACE VECTORS IN PRE-CLINICAL MODELS OF 
RETINITIS PIGMENTOSA ..............................................................................................  066 
I. INTRODUCTION ....................................................................................  066 
II. RESULT .................................................................................................  068 
III. DISCUSSION .........................................................................................  076 
IV. FUTURE DIRECTIONS ............................................................................  078 
 
CHAPTER 5: MATERIAL AND METHODS (FIRST PART) ................................................  079 
 
CHAPTER 6: ESTABLISHMENT OF GENE CORRECTION TOOLSET FOR DOYNE HONEY 
COMB DYSTROPHY ......................................................................................................  085 
I. INTRODUCTION ....................................................................................  085 
II. RESULT .................................................................................................  086 
iii 
 
III. DISCUSSION .........................................................................................  095 
 
CHAPTER 7: IPSC REPROGRAMING AND RPE DIFFERENTIATION ...............................  096 
I. INTRODUCTION ....................................................................................  096 
II. RESULT .................................................................................................  097 
III. DISCUSSION .........................................................................................  102 
 
CHAPTER 8: PHENOTYPING OF PATIENT IPSC-DERIVED RPE ......................................  103 
I. INTRODUCTION ....................................................................................  103 
II. RESULT .................................................................................................  104 
III. DISCUSSION .........................................................................................  112 
IV. FUTURE DIRECTIONS ............................................................................  115 
 
CHAPTER 9: MATERIAL AND METHODS (SECOND PART) ...........................................  116 
 










LIST OF FIGURES  
Figure 1. Structure of the retina ...................................................................................... 1 
Figure 2. The phototransduction signaling ...................................................................... 6 
Figure 3. Repair of DNA double strand break ...............................................................  27 
Figure 4. Components of CRISPR technology: Cas9 protein and gRNA ......................... 28 
Figure 5. Subretinal and intravitreal injection ............................................................... 36 
Figure 6. Illustration of Ablate-and-Replace gene therapy strategy .............................. 44 
Figure 7. Illustration of double (CRISPRd) or single (CRISPRs) gRNA strategies to      . 
specifically ablate mouse Rho exon 1 ........................................................... 45 
Figure 8. Modified pX459 vectors for CRISPRd and CRISPRs ......................................... 46 
Figure 9. Genetic and expression outcomes following CRISPRd- vs CRISPRs-mediated      . 
gene editing .................................................................................................. 47 
Figure 10. Validation of mRho exon 1 truncation ......................................................... 48 
Figure 11. Schematic summary of the basic outcomes produced by CRISPRd- and       . 
CRISPRs-mediated gene editing .................................................................... 49 
 Figure 12. Schematic design of primers to generate truncated Rho promoter with      . 
different length ............................................................................................. 52 
Figure 13. Plasmid expressing transcription factors CRX, NRL and NR2E3 .................... 53 
 Figure 14. Testing of Rho promoter reporter ............................................................... 54 
Figure 15. Different Rho promoters exhibit similar driving efficiency ........................... 55 
Figure 16. Schematic of experimental (AAVs-Cas9+GR) and control (AAVs-Cas9+SR)      . 
AAV2/8 vector pairs ...................................................................................... 56 
v 
 
Figure 17. Conventional gene replacement therapy vs CRISPRd plus gene replacement,      . 
compound therapy for a heterozygous loci ..................................................  57 
Figure 18. The gRNAs sequences, their targeting sites on mRho and the corresponding       . 
sites on hRHO................................................................................................. 58  
Figure 19. Representative data of in vitro SpCas9/gRNA cutting .................................. 58  
Figure 20. Experimental scheme and timeline for subretinal injection of dual AAV       . 
vectors in right eyes of wild-type C57BL/6J mice ........................................... 59 
Figure 21. Representative data of Cas9-immunostaining in retinal flat mount ............ 60 
Figure 22. Representative data of PCR analysis of retinal genomic DNA from               . 
AAVs-Cas9+GR-injected right eyes and uninjected, fellow (left) eyes ........... 60 
Figure 23. Representative data of mRho gene ablation validated by Sanger sequencing     .  
of PCR amplicon from Fig. 22 ..................................................................... 61 
Figure 24. Gene ablation and replacement are co-localized in rod photoreceptors in     . 
vivo ................................................................................................................ 62 
Figure 25. Schematic of two different AAVs distribution scenarios .............................. 65 
Figure 26. The amino acids of P23 and D190 on Rho structure .................................... 67 
Figure 27. Experimental and disease progression timelines ......................................... 69 
Figure 28. Therapeutic effect of RhoP23H/P23H mice ........................................................ 70 
Figure 29. Therapeutic effect of RhoP23H/+ mice ............................................................ 73 
Figure 30. Therapeutic effect of RhoD190N/+ mice .......................................................... 75 
Figure 31. gRNA targeting sites ..................................................................................... 86  
Figure 32. In vitro gRNA targeting ................................................................................. 87 
Figure 33. Donor template design ................................................................................. 88 
vi 
 
Figure 34. Optimization of nucleofection program ........................................................ 90 
Figure 35. Sequencing result of iPSC colonies after gene correction ............................. 94 
Figure 36. Immunostaining of TRA-1-60 and SOX2 ........................................................ 97 
Figure 37. Immunostaining of SSEA4 and OCT4 ............................................................. 98 
Figure 38. iPSC culture of RPE differentiation before and after colonial enrichment …. 99 
 Figure 39. Morphology of iPSC-derived RPE after 200 days of differentiation ........... 100 
Figure 40. Immunostaining of RPE marker. Anti-BEST1 (red) and DAPI (blue) were used      .  
to stain iPSC-derived RPE ............................................................................ 101 
Figure 41. Real-time analysis of unfolded protein response biomarkers .................... 104 
Figure 42. ELISA analysis of pro-inflammatory cytokines ............................................ 106 
Figure 43. Proteomics analysis on patient-iPSC-derived RPEs by LC-MS/MS .............. 108 
Figure 44. Volcano plot comparing proteomic profiles between patient and wildtype     .   
iPSC-derived PREs ........................................................................................ 109 
Figure 45. Volcano plot comparing proteomic profiles between gene-corrected and    .   
mutant iPSC-derived RPEs ............................................................... 110 
Figure 46. Protein level changes after gene correction ............................................... 111 
Figure 47. Hypothesis illustration of potential mechanism resulting intracellular lipid       .   
accumulation ............................................................................................... 113 
Figure 48. Medium and components used for RPE differentiation …………………………… 118 






I would first like to thank my advisor, Dr. Stephen Tsang for his guidance and mentorship 
over the years. He provided an excellent environment for me to broaden my sight in 
science. He taught me how to think about science, how to do science, and especially, how 
to argue science. It has been an honor to work in his lab. I am also grateful to my thesis 
committee members and other faculty mentors for their insightful suggestions and 
helpful advice throughout my PhD research. I also like to thank my colleagues and lab 
mates who have provided remarkable support and collaboration to my research. Finally, 
I would like to thank my wife Wen-Hsuan, who has provided me through moral and 




THE EYE AND THE RETINA  
BRIEF OVERVIEW OF THE EYE AND THE RETINA 
The eye is a sophisticated organ that provides information on the shape, light 
intensity, and color reflected from objects. The eye ball can be divided into two segments: 
anterior and posterior parts. The anterior segment comprises of the cornea, lens, iris and 
ciliary body, while the posterior segment consists vitreous, retina, and choroid. The eye 
ball can also be divided into three layers: the outermost layer for protection layer (sclera 
and cornea), the middle layer, the nutritive layer (the choroid, ciliary body and iris), and 
the innermost layer, neural sensory layer (the retina). Each layer has its importance; 
however, the focus in this section will be the retina. 
 
 




The retina is like the film or CCD of the camera. Retina contains at several types of 
different neuron cells that form more than 30 distinct synapses with one another (Fig. 1). 
The primary light sensitive neurons, called the photoreceptor cells, lie in the outermost 
layer of retina. The other retina cells, in order from the photoreceptor cells inwards: 
Müller glial cells, amacrine cells, bipolar neurons, horizontal cells, and the innermost 
ganglion cells1. A layer of pigmented epithelium cells called retinal pigment 
epithelium (RPE) lies outwards to photoreceptor layer. RPE nourishes retinal visual cells, 
and is firmly attached to the underlying choroid and overlying retinal visual cells. RPE cells 
help nutrients and oxygen exchange from the choroid to photoreceptor. 
The photoreceptor cells are very essential neuronal cells that can be divided into 
four counterparts: the outer segment (OS), inner segment (IS), soma, and a synaptic 
terminal for neurotransmission to the second-order cells of the retina. There are two 
types of photoreceptor, the rod and cone cells. Rod cells comprise approximately 97% of 
the total retinal photoreceptors, whereas cone cells make up the only 3% of the retinal 
photoreceptor cells in both mouse and human retinas. The IS segment in both of the rod 
and cone cells contains ribosomes, mitochondria, and ER membranes that are used to 
assemble and transport opsin molecules to the OS discs. In the rod cells, the OS features 
invaginations of the plasma membrane at its base, which makes detached stacks of disc 
structures. As for the cones, the discs remain attached to the OS membrane. The RPE cell 
pseudopodia continually renews these OS discs by separating the distal disc from the four 
remaining stack. These shed discs are then phagocytosed by RPE and degraded. This 
process can keep the photoreceptor cell OS length constant.  
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Each photoreceptor cell features a specific role for the type and amount of 
light that results in its unique signaling response. Rod cells are sensitive photoreceptors 
that respond to single photons of light. Therefore, they are active in dim-light 
settings and thus enable for night-time vision. Rods principally have a 
response range of three orders of magnitude, up to 10,000 photons per second (mesopic 
vision), at that point they saturate2-4. Once the rods saturate, the cones begin to 
activate (photopic vision). By shifting their operating curves, cones take the human 
eye out to more than ten billion photons per second.  
There are completely different variations of cone cells, each accountable for 
sensing different wavelengths of light, and thus granting day-time, sight. In humans, there 
are three kinds of cone cells: the S-cones, L-cones, and M-cones. The macula, a central 
region of the retina, is enriched in cone cells, causing the cones to be accountable for the 
central visual field whereas the rod cells comprise the majority of the peripheral visual 
field2, 3, 5. Using the photoreceptor cells’ sensitivity to photons, the retina takes 
responsibility for two major functions of vision. One, it transduces photons into neural 
signals; and second, these neural signals are then transmitted to the brain in a manner 
within which the brain will acknowledge and decipher the visual image. Retinal circuits 
transform patterns of light and darkness on the photoreceptor mosaic of the retina, and 
these patterns result in repetitive discharges from a two-dimensional array of ganglion 
cells to the brain. Over the past years, progress has been done in understanding the 
mechanisms of neurocircuitry and phototransduction in the retina. No feedback from the 
brain to the retinal cells occurs during the visual process, and thus the phototransduction 
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signaling cascade in the photoreceptor rods and cones is of high importance to provide 
correct visual images. 
 
PHOTOTRANSDUCTION CASCADE  
The photoreceptor cells contain opsins within the OS discs, which are 
photosensitive pigments that photoactivate once light exposure. Every OS disc contains 
several million opsin molecules. These photoexcited opsins then stimulate the plasma 
membrane of the photoreceptors to trigger signals that are transmitted through the inner 
retina, to the optic nerve, and on to the brain. In the dark, there is a current that flows 
from the IS to the OS of the photoreceptor cell. After light exposure, the OS undergoes a 
process, known as the phototransduction cascade that interrupts this cell current. This 
cascade happens on the stacks of disc membranes and results in altered cyclic guanosine 
monophosphate (cGMP) levels in the photoreceptor OS. The fluctuation in cGMP levels 
in the photoreceptor transmits the light response signal from the OS discs to the cell 
membrane of the photoreceptor cell6. This process is rigorously regulated by numerous 
molecules, each of which is responsible for the activation, deactivation, and adaptation 
of the phototransduction cascade in the photoreceptor cell. The phototransduction 
cascade is activated once light is absorbed by a molecule in the OS of the photoreceptor, 
known as rhodopsin (RHO). Rho protein is a seven-loop transmembrane G-protein 
coupled receptor that contains a protonated Schiff base with a lysine side chain. This 
lysine side chain is covalently conjugated to an 11-cis chromophore7, 8. A photochemical 
event happens after light sensation to the photoreceptor cells that causes the geometrical 
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photoisomerization of the pigment 11-cis retinylidene chromophore into an all-trans 
configuration9. After light stimulation, this pigment will no longer be photoactivated. 
Therefore, a mechanism exists within the retina to regenerate these light-sensing 
pigments. The all-trans retinylidene is isomerized back into the 11-cis configuration, to 
produce a pigment that can be photoactivated by light. This whole process is known as 
the visual cycle. 
In the vertebrate, the Schiff base link between the chromophore and opsin is 
hydrolyzed, that permits for free all-trans retinal to be discharged. This is a process called 
bleaching9. This all-trans retinal is then reduced within the photoreceptor cell by 
NAD(P)H-dependent retinol dehydrogenases (RDHs) to yield all-trans retinol, otherwise 
referred to as vitamin A. All-trans-retinol is transferred into the RPE cell layer to be 
esterified by lecithin: retinol acyltransferase (LRAT) for storage9. In the RPE cells, stored 
all-trans retinyl esters are isomerized to 11-cis retinol by retinal pigment epithelial 65 
kilodalton (RPE65) protein. This happens in a complex enzymatic reaction that involves 
the concurrent hydrolysis of the ester moiety. The 11-cis retinol is then converted to 11-
cis retinal. 11-cis retinal then passes out of the RPE and into the outer segment of the 
photoreceptor cell to bind to opsin and form the RHO molecule. 
While there are three unique opsins in cone cells, the RHO gene encodes the sole 
opsin in rod cells. RHO is firstly synthesized and modified by N-Glycosylation into the 
endoplasmic reticulum. In Golgi apparatus, proteins are further assembled into vesicles, 
to be exported from the inner segment of photoreceptor through the connecting cilium 
into the outer segment, where rhodopsin proteins (RHO) are directly integrated into the 
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disc membranes. RHO is a special G protein-coupled receptor, with seven trans-
membrane domains, which can be assembled with the 11-cis-retinal chromophore 
(derivative of vitamin A), to function. When the photon enters into the retina, photons 
are captured by the 11-cis-retinal. This molecule will undergo a conformational change 
(isomerization) to all-trans-retinal isomer. This reaction is the first step of 
phototransduction cascade (Fig. 2). 
 
 
Figure 2. The phototransduction signaling. 
 
Light causes this RHO molecule to an activated state with conformational change. 
This product is called metarhodopsin II (Rh*). Rh* next activates it downstream molecules 
transducin (Gtαβγ). Gtαβγ are heterotrimeric G-proteins which can act by exchanging 
7 
 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP)10. This activation by Rh* 
causes GTP to bind to the Gtα subunit of Gtαβγ. Then, this Gtα-GTP dissociates from the 
Gtβγ portions of Gtαβγ. Once dissociation, the Gtα-GTP binds to the inhibitory γ subunits 
of cyclic guanosine monophosphate (cGMP)-phosphodiesterase 6 (PDE6).  
PDE6 is a heterotetrameric protein consisting of a catalytic α-subunit, a catalytic 
β-subunit, and two inhibitory γ-subunits within the rod photoreceptor cell. In the cone, 
PDE6 consists of a catalytic dimer that contains two identical α’ subunits, instead of the α 
and β subunits found in the rod. In addition, the γ’ inhibitory subunits of the cone PDE6 
differ slightly in size and amino acid composition from the rod γ inhibitory PDE6 subunits6. 
PDE6 is highly essential in the phototransduction cascade, because it is the primary 
regulator of cytoplasmic cGMP concentration in the photoreceptor cells. In the dark, PDE6 
is in an inactive form, with the γ inhibitory subunits attached (PDE6αβγ), and cGMP level 
inside the photoreceptor cell OS is high (several micromolars)6. This permits for cGMP-
gated Na+/Ca2+ ion (CNG) channels in the plasma membrane to stay open, allowing a 
current to circulate through the photoreceptor cell.  
After light stimulation of the phototransduction cascade, the binding of Gtα-GTP 
on the γ-subunits of PDE6 eliminates the inhibition on the catalytic α- and β-subunits of 
PDE10, 11. The activated PDE6 hydrolyzes cGMP, breaking it down and lowering its 
concentration within the photoreceptor cell. This light-activated PDE is about three 
hundred times greater active than in its basal state, swiftly breaking down the cyclic 
nucleotide levels12. The fast reduction of cGMP within the photoreceptor cell after light 
stimulation of the phototransduction cascade causes the CNG channels located in the 
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plasma membrane to shut. Consequently, the levels of Na+ and Ca2+ into the cytoplasm 
are decreased, causing the rod cell to become hyperpolarized. Hyperpolarization of the 
rod cell causes it to lower glutamate at its synaptic terminal to signal to the other neuronal 
cells of the retinal and on to the optic nerve and the brain. 
After light stimulation, the phototransduction cascade has to undergo 
deactivation to return cGMP to its basal levels. The photoexcited Rh* is inactivated via 
the phosphorylation of threonine and serine residues at its carboxyl tail by a rhodopsin-
specific kinase known as G protein-dependent receptor kinase I (GRK1)13. This 
phosphorylated rhodospin (Rh*-P) has greater efficiency binding toward a molecule 
called arrestin (Arr; also known as S-antigen), instead of Gtα. Arr inhibits the removal of 
the phosphate groups on Rh*-P14. This hastily reduces the amount of dephosphorylated, 
active Rh* available for the activation of Gtα and the rest of the phototransduction 
cascade. 
Moreover, Gtα has intrinsic GTPase activity to inactivate itself after its binding to 
the γ inhibitory subunits of PDE612. The PDE6αβ catalytic subunits re-associate with the 
two PDE6γ subunits for inactivation of the PDE6 complex while retinal guanylate cyclases 
(Ret GC-1 and Ret GC-2) become activated and reproduce cGMP within the photoreceptor 
cell13. The recovery of the basal cGMP concentration in the photoreceptor cell re-opens 
the CNG channels. The deactivation process is now complete. Activation of the 
phototransduction cascade begins again while Rh*-P-Arr binds to 11-cis retinal which 
releases the molecule from Arr. The Rh*-P is then dephosphorylated by phosphatase 2A 
and the light/dark activation/deactivation cycle can continue in the photoreceptor cell. 
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In addition to the activation and deactivation of the phototransduction cascade, 
there is also the photoreceptor adaptation to constant light stimulus. As formerly referred 
to, light stimulation of the phototransduction cascade ends in the closure of the CNG 
channels in the photoreceptor OS. This induces a decline in Ca2+ influx into the 
photoreceptor. Intracellular Ca2+ levels act to inhibit the guanylate cyclases (Ret GC-1 
and Ret GC-2). Consequently, Ret GC-1 and Ret GC-2 are activated when light stimulates 
the phototransduction cascade and Ca2+ levels reduce within the cell15-17. This occurs 
through the stimulation of Ret GC-1 and Ret GC-2 with the aid of the guanylate cyclase 
activating proteins (GCAP-1/p-20 and GCAP-2/p24). These guanylate cyclases work to 
create more cGMP to counteract the reduction in cGMP by PDE6 after the activation of 
the phototransduction cascade. 
Additionally, a molecule known as recoverin then mediates the Ca2+ sensitivity of 
GRK1 phosphorylation of Rh*. For that reason, extended light leads to a decrease in Ca2+ 
levels and induces GRK1 activity by decreasing recoverin’s inhibition of GRK115-17. 
Furthermore, the CNG channel, accountable for the ionic current of the photo-response, 
binds a molecule called calmodulin at high levels of Ca2+, and extended light reduces 
calmodulin binding and leads to a decline in the channel affinity for cGMP. This causes 
the channel to re-open at lower levels of cGMP than it would in dark environment. 
Lastly, light adaptation results in a greater inhibition of the PDE6 enzyme to permit 
for a speedy reduction in the hydrolysis of cGMP. Ca2+-sensitive members of the protein 
kinase C family phosphorylate the two PDE6γ subunits. This phosphorylation site is 
blocked while the γ subunits are bound to PDE6αβ, but light activation of the 
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phototransduction cascade allows for Gtα-GTP to discharge the γ inhibitory subunits from 
the PDE6αβ complex. After GTP hydrolysis, free PDE6γ are then phosphorylated by 
members of the protein kinase C family at threonine 35, which permits them to re-bind 
to PDE6αβ and cause a stronger inhibition of the catalytic activity of PDE6. 
Any alterations of the phototransduction cascade, such as changes affecting the 
renewal and shedding of the photoreceptor OS or visual transduction, or even retinol 
metabolism can have a remarkable impact on the retinal integrity. Mutations within any 
of the related molecules accountable for those visual processes may cause numerous 
types of retinal and RPE degenerative conditions. The majority of retinal degenerations 
are caused by gene defects, leading to a lower protein levels or incorrect protein functions. 
For instance, the inability of the RPE to phagocytose the photoreceptor OS causes a type 
of autosomal recessive retinitis pigmentosa (arRP). This disease and other retinal 
















Unfortunately, retinal degeneration is a common occurrence in the world. The loss 
of sight affects about 3.4 million people in the United States. Alone and is predicted to 
increase over the years19. Visual impairment ranks merely behind arthritis and 
cardiovascular disease with respect to disease impact on function in the elderly. In fact, 
visual loss is frequently considered by patients to be their dominant health issue, even in 
the presence of other chronic disabling disorders20. Patients experience a loss of quality 
of life, as they require assistance in daily tasks such as walking, reading, or driving.  
There is great genetic and allelic heterogeneity of the several retinal dystrophies. 
These conditions have been categorized using age of onset, electrophysiological and 
psychophysical studies. However, those classifications can be ambiguous as there are 
comparable clinical presentations in retinal degenerations arising from different genetic 
mechanisms. For example, RP can be caused by both mutations within proteins of the 
phototransduction cascade, such as RHO or PDE6, and also by mutations within rod OS 
membrane proteins, such as peripherin21, 22. Moreover, different mutant alleles at the 
identical locus can cause diverse clinical manifestations of disease. For instance, 
mutations in the β subunit of PDE6 can cause different kinds of retinal degenerative 
diseases: such as congenital stationary night blindness or RP21, 22. Currently, the most 
accurate method of classification is based on the specific molecular genetic defect, and 





As mentioned, photoreceptor neurodegenerative diseases have great impacts on 
both patients and society. Unfortunately, they there is no cure18, 23-26. One of the most 
devastating photoreceptor degenerative diseases is retinitis pigmentosa (RP), which is the 
focus of this study. RP is the most common cause of hereditary blindness in the world, 
affecting about 1:3000 people18, 26. There are various forms of RP, including autosomal 
dominant (15-20% of cases), autosomal recessive (20-25% of cases), and X-linked (10-
15%). The remaining 40-55% of cases is currently of unclassified inheritance23, 26-30. Those 
unclassified RP patients are typically due to the absence of familial histories, and are 
denoted as simplex RP. Most simplex RP cases are believed to be autosomal recessive30. 
Autosomal dominant forms of RP are generally the mildest, with onset that can occur as 
late as 50 years of age. Autosomal recessive, however, are more severe and disease onset 
normally occurs during the first decade of life26, 30. Moreover, RP can be secondary in 
etiology and is involved in more than 30 disease syndromes. 
Genetically, most forms of RP are monogenic, even though there have been cases 
of digenic-diallelic and digenic-triallelic inheritances. Due to RP being both locus 
heterogenous and phenotypically heterogenous, mutations in no single gene are known 
to cause greater than 10% of 14 cases of RP30. In 2013, there are 45 genes mapped that 
cause non-syndromic forms of RP, although there is likely to be many more genes 
responsible for this disease as about 200 more genes have already been identified that 




Table 1. Genes associated with autosomal dominant retinitis pigmentosa (adRP). 
Adapted from sph.uth.edu/retnet/ and Fahim et al., GeneReviews, 199323. 
 
 In RP, the progressive atrophy of the rod photoreceptor cells results in the 
secondary death of the cones. Affected individuals will present with night blindness, 
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tunnel vision, and eventual loss of central vision when cone cells degenerate. This 
photoreceptor cell death has been thought to result from a caspase-dependent apoptotic 
mechanism, as was observed in animal models of retinal dystrophies31, 32. However, there 
have been recent research suggesting that other disease pathways, such as calpain-
mediated cell death or proteasome activity, may be responsible for the degeneration of 
the photoreceptor cells13, 33, 34. Although it stays to be elucidated which death mechanism 
leads to the loss of the photoreceptors, RP can be categorized into three stages of clinical 
disease. 
In stage I of RP, patients usually present with night blindness. While some patients 
ignore this symptom, and typically will not recognize the disease phenotype until the 
teenage years, when they attend evening events. There are not any visual defects 
presented in the daylight, and patients have normal life activities. Only the 
electroretinogram (ERG), a clinical test that measures the electrophysiological response 
of the retinal cells to flashes of varying light intensities, will display a loss of visual 
response at this time27, 29. Hence, at the early disease stage most patients will not be 
clinically diagnosed with RP.  
In the mid-stage of RP, patients will have difficulty performing   nighttime activities, 
such as driving, and will become aware of a loss of their peripheral visual field even in the 
daylight. Moreover, patients may become photophobic, especially in regards to diffuse 
light, such as cloudy weather days27, 29. This imposes difficulty reading and performing 
daily activities. At this stage, patients notice the disease phenotype, visit a clinician, and 
are generally diagnosed with RP.  
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At the clinic, fundus examination will show the presence of bone-spicule shaped 
pigment deposits in the mid-periphery of the retina, along with retinal pigment epithelial 
atrophy. Narrowing of the retinal vessels is also obvious at this time. ERG examination will 
display an attenuated visual response in the cone cells, and a complete loss of visual 
response under scotopic, dark-adapted conditions27, 29. This phenomenon reflects the loss 
of the majority of the rod photoreceptor cells. 
In the final stage of RP, the clinical manifestations that occur in the mid-stage of 
the disease will worsen until the patients have lost their ability to perform daily tasks on 
their own, without assistance from others. They will then continue to deteriorate until 
the loss of their central visual field, rendering them blind. This disease not only affects the 
patient and their cherished ones, but society as a whole. RP patients have progressively 
declining vision that inevitably leads to blindness, and society is confronted with the high 
costs of caring for each of these visually handicapped persons for the remainder of their 
lives. 
RP is arguably one of the best model for studying neurodegenerative diseases, for 
three main reasons. First of all, the basic pathogenic process in RP, that of rod cell atrophy 
leading to a secondary, non-autonomous death of the cone cells, is generalizable to other 
types of retinal degenerative diseases, such as age-related macular degeneration (AMD) 
or even normal aging13.  
Secondly, many mouse models now exist for mutations in Rho leading to RP, which 
is the most common cause of autosomal dominant RP13. Third, in contrast to mouse 
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models of EYS35 or ABCA436, common photoreceptor degenerative diseases in which the 
mouse model does not mimic human disease, these mouse models with loss of function 
of Rho mimic the human phenotype37, 38.  
More than 120 single nucleotide mutations have been reported in RHO gene, each 
of them can lead to retinal degeneration. Within those RHO mutation-induced retinal 
degeneration, most of them can cause autosomal dominant retinitis pigmentosa (adRP), 
but also sometimes autosomal recessive RP (arRP) or congenital stationary night 
blindness. These mutations are homogeneously distributed on RHO gene. Every mutation 
can cause disease through different mechanisms. These pathogenesis based on diverse 
RHO mutations can be classified into several groups.  
 
 
Table 2. Classification of rhodopsin mutations. Adapted from Mendes et al., TRENDS in 
Molecular Medicine, 200539. 
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For instance, P23H mutation, which belongs to class II RHO mutations, has been 
described to be retained in the ER in cellular models40, 41. This has been suggested to 
induce the unfolded protein response, which can lead to apoptosis42. This mechanism 
could be an explanation for photoreceptor degeneration, however this theory is still 
under debate in the in vivo context43, 44. 
Scientists and clinicians have started searching for therapeutic agents that will be 
effective in slowing the photoreceptor cell death, and/or curing the causative genetic 
defect. 
 
DOYNE HONEY COMB DYSTROPHY 
Doyne Honey Comb Dystrophy (DHRD) is an inherited condition that affects the 
eyes and causes vision loss. This disease was described initially in inhabitants or 
descendants of the Leventine valley of Tessin Canton in Southern Switzerland45. A R345W 
mutation can be found in EGF Containing Fibulin Extracellular Matrix Protein 1 (EFEMP1) 
from all the DHRD patients46, 47. 
DHRD is characterized by small, round, yellow-white deposits known as drusen 
that accumulate between the retinal pigment epithelium (RPE, the nutritive layer 
of cells deep in the retina that helps maintain the function of the photoreceptor cells) and 
Bruch’s membrane (BrM)46-48. The thin BrM is a pentalaminar matrix located between RPE 
and choroid. BrM is a semipermeable filtration barrier through which major metabolic 
exchange takes place49. BrM has five layers (from the innermost to the outermost): the 
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RPE basement membrane, the inner collagenous zone, the elastic zone, the outer 
collagenous zone, and the choriocapillaris basement membrane. The inter fiber matrix of 
BrM is principally composed of heparin sulfate, chondroitin or dermatan sulfate. The 
chondroitin sulfate in BrM is believed to provide an electrolytic barrier to diffusion.   
When DHRD progress over time, drusen may enlarge and come together, creating 
a honeycomb pattern. At this point, patients may start to notice changes in their visual 
acuity (the clarity or sharpness of vision)50-52.  Typically, people with DHRD do not have 
symptoms until 30-40 years of age. Early visual symptoms may include: decreased visual 
acuity; problems seeing color; relative scotomas (a defect in the visual field resulting in 
problems seeing objects of low brightness); photophobia (eye discomfort in bright 
light); and metamorphopsia (distorted vision). In the later stages of the condition, usually 
by the age of 40 to 50 years, one's central vision deteriorates. Additionally, absolute 
scotomas can develop. These visual defects (which are surrounded by normal visual 
field) are associated with total loss of vision within that specific area.  
DHRD is usually characterized by slowly progressive loss of central visual acuity. To 
some extent, the degree of severity is associated with age. Mild cases are usually 
detected between 20 to 40 years of age52. They are characterized by normal vision and 
the presence of small, discrete drusen in the macula. More severe cases generally occur 
at or after 50 years of age and are associated with profound loss of visual acuity.  
However, the severity of symptoms in DHRD can be variable. There are always ex
ceptions to the "typical" age of onset and course of DHRD. For example, there have been 
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reports of people with DHRD in their sixties who still have good vision.  In other affected 
people, their disease course may change to one of faster progression and severe visual 
loss if choroidal neovascularization (CNV) occurs48, 53-55. CNV involves the growth of new 
blood vessels from the choroid into the subretinal space, and is a major cause of visual 
loss56.  
The importance of these diseases is due in large part to their close phenotypic 
similarity to age-related macular degeneration (AMD), a disorder with a strong genetic 
component that accounts for approximately 50% of registered blindness in the Western 
world57-60. Just as in ML and DHRD, the early hallmark of AMD is the presence of 
drusen61. Though in AMD, no genetic or other causative factor has been found. 
The origin of drusen is still a mystery. Drusen is discrete extracellular deposits that 
commonly precede the development of AMD, and that are comprised of numerous 
cellular and inflammatory factors. Other than mutant EFEMP1 protein itself62, RPE 
basement membrane molecules such as collagen IV, VI, laminin, and heparan sulfate 
proteoglycans were found in drusen63-66. Other proteins such as vitronectin, MMP-7, 
TIMP-3, C3, and C5b-9 have also been reported67, 68. 
Lipid particles accumulate within Bruch’s membrane in the exact location and 
prior to the development of basal deposits or drusen. This observation has led to the 
hypothesis that these lipid particles contribute to drusen formation during the 
development of AMD. Recent work suggests that the lipoprotein particles found within 
Bruch’s membrane are distinct from plasma lipoproteins and have been found to contain 
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free and esterified cholesterol, phosphatidylcholine (PC), and apolipoprotein B10069, 70. 
Curcio et al. found that esterified cholesterol comprised 60% of total cholesterol within 
these lipoproteins, and esterified cholesterol was 7-fold higher in the macula than 
periphery71. It has been speculated that membranous debris is membrane-bound packets 
of RPE cytoplasm released by the RPE72 or RPE basal in foldings disintegrating with age73. 
This secretion of basement membrane-like material and lipid particles, may polymerize 
or condense to produce long spacing collagen and dense amorphous material, and finally, 

















THERAPY FOR GENETIC DISEASES 
BRIEF OVERVIEW OF CURRENT EXPERIMENTAL THERAPIES  
Patients with RP are not curable, and at this time there are not any standard 
treatments in clinical practice to halt the progression of photoreceptor degeneration and 
loss of vision. However, there are numerous methods being studied to try to slow down 
the rate of degeneration and allow for patients to extend the time in which they are able 
to maintain their central visual field. One approach used for patients with RP is to provide 
dark sunglasses for use outdoors, in order to block the amount of light to the 
photoreceptor cells26, 30. Since a majority of RP cases are caused by mutations within the 
phototransduction cascade, which is activated by light, this decreases the effects of those 
mutations by limiting the light stimuli. Moreover, yellow-orange glasses block 
photophobic effects for patients and are suggested by some clinicians26, 30. However, 
those methods for protecting the photoreceptor cells cannot offer a cure for the disease, 
and various other therapeutic options are being tested for RP patients.  
A main research that was conducted examining the effects of vitaminotherapy for 
RP. Vitamin A was hypothesized to protect the photoreceptor cells through a trophic 
effect, and vitamin E via anti-oxidant protective effects26, 30. Studies have shown that long-
term supplementation of daily vitamin A was capable to slightly ameliorate the loss of 
visual function as observed by the cone ERG b-wave amplitude in RP patients. However, 
400 units of vitamin E per day had unfavorable effects in RP patients23, 27, 30. Since vitamin 
A is stored within the body, patients taking vitamin A supplementation at high doses have 
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to be monitored as well for potential toxicity, and clinicians debate the usefulness of this 
treatment. 
Another method is to provide RP patients 1200mg/day of docosahexanoic acid 
(DHA) supplements in addition to the vitamin A supplementation, which showed an initial 
slowing of the disease progression in trials, but one which did not last in patients beyond 
two years of follow-up75-77. Moreover, patients with the ABCA4 gene mutation that leads 
to Stargardt’s disease, another retinal degenerative disease, have negative effects after 
vitamin A supplementation75-77. Those are the most promising treatment options at this 
time for RP, and whether or not they will have any significant slowing of retinal 
degeneration is controversial.  
Some other choice is to apply pharmacological treatments if the mechanism of 
degeneration is known for the patient. Animal studies have tested the use of calcium 
channel blockers to slow down RP progression. This is thought to be effective since 
increases in cGMP leads to a constant opening of the CNG channels and alters the ion 
current to cause photoreceptor cell death. However, those animal studies have shown 
limited success75-77. One of the promising pharmacological treatments analyzed the 
effects of 9-cis retinal in mouse models of Leber congenital amaurosis (LCA), an early-
onset blinding disorder. LCA patients have mutations in RPE65, the isomerase that acts in 
the visual cycle for the conversion of all-trans retinyl esters to 11-cis retinal for binding to 
opsin. 9-cis retinal is assumed to be able to bind opsin and create a modified form of 
rhodopsin that can be activated by light and function in the phototransduction cascade. 
Delivery of 9-cis retinal to the Rpe65-/- mouse model of LCA has restored rod cell function, 
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however further studies are necessary to determine the efficacy of rescue for this 
pharmacological treatment75-77. 
Other pharmacological therapies include treating mouse models of Stargardt 
disease, a blinding disorder which is believed to involve the accumulation of bisretinoid 
lipofuscin in the RPE, with visual cycle inhibitors. Those studies have also found some 
slowing in the accumulation of lipofuscin, thought to lead to the RPE-related disease 
phenotype 75-77. As more genetic mutations and mechanisms of retinal degenerative 
diseases are recognized, pharmacological treatments can become more targeted and 
better developed. These agents are promising, and may have the potential to be 
beneficial therapeutic options to decelerate the progression retinal degenerative diseases, 
such as RP.  
Another treatment method is to use growth factors to form neuroprotection to 
the photoreceptor cells and thus limit photoreceptor degeneration. Animal models have 
shown therapeutic efficacy using an array of growth factors, including ciliary neurotrophic 
factor, brain-derived neurotrophic factor, and glial-derived neurotrophic growth factor75-
77. However, these growth factors have to be introduced in situ to the animal, due to the 
short half-life of the growth factors. Many strategies are being developed for this drug 
delivery, such as gene transfer and the use of encapsulated cells placed into the vitreous 
cavity75-77. However, these growth can have side effects that include cataract, which could 
lead to a loss of vision. The application of ciliary neurotrophic factors is currently in phase 
I of human clinical trials for patients with RP; however it has been shown to lower the ERG 
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response in some animal models of retinal degeneration, suggesting a potential 
unwanted effect of the growth factor or delivery system75-77. 
Besides treatments that may only decelerate the progression of retinal 
degeneration, scientists are also working on strategies to replace the already 
degenerated photoreceptor cells. One method in which to achieve this goal is to use 
retinal prosthetic devices. Those devices incorporate microphotodiode arrays that are 
able to capture light and stimulate the retina. They can be incorporated into the eye to 
act in the phototransduction cascade, or they can be included in sites accountable for 
later stages of the visual signaling cascade. Those sites include directly stimulating the 
optic nerve or the visual cortex of the brain. One of these early retinal prothestic devices 
has been approved by the Federal Drug administration and is proven to be tolerated by 
the human patients after implantation75-77. However, these devices are not yet a standard 
therapy for RP, but further studies and improvements in the prosthetics can make them 
a feasible option.  
Another method to replace the degenerated photoreceptor cells is to transplant 
cells from fetal or adult retina into patients. In current published cases, researches 
transplantation studies using photoreceptors allowed survival of the transplanted cells 
within the host diseased retinas, however they were not able to arrange and organize 
themselves to provide proper structure and synaptic connections75-77. An alternative 
therapy will be the use of stem cells, by using either embryonic or patient-derived induced 
pluripotent stem cells, to create sheets of cells or tissues for transplantation into patients 
with RP. Promising results from cell transplantation experiments have been found in 
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animal models of retinal degenerative diseases. RPE grafts have been proven to rescue 
both the Royal College of Surgeons (RCS) rat and the Rpe65-/- mouse models78, 79. 
Nevertheless, these therapies are still undergoing development and more studies have to 
be done before one can create a purified cell or tissue of interest in vitro that will be able 
to make all the essential synaptic connections in vivo after transplantation. 
 
GENE THERAPY  
Gene therapy has become a promising therapeutic tool for treating blindness due 
to inherited retinal degenerative diseases. Current technology has allowed for the 
elucidation of disease-causing alleles and specific genetic defects, which grants scientists 
the capability to create a gene therapy vector which can target those specific genes of 
interest. There are numerous vectors that can be applied for gene therapy, including both 
viral and non-viral vectors. Though usually, to maximize the transduction efficiency, viral 
vectors are used; although small molecules are now being created that have the potential 
to efficiently transfect the cells of the retina.  
The first viral vector to be developed for use in gene therapy was the lentivirus. 
Lentiviruses were of interest because of the fact that they could hold approximately 9 
kilobases (kb) of deoxyribonucleic acid (DNA), and more importantly, infect non-dividing 
cells, such as the photoreceptor cells13, 23, 75. Lentiviral vectors take advantages of   the 
human immunodeficiency virus (HIV) genome. Second and third generation lentiviruses 
are being developed, in which several regulatory proteins are deleted from the packaging 
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construct80. At present, only the in vivo potential pathogenicity of the HIV-1 based viruses, 
such as lentiviruses, can be determined by in vitro tests, and more technical 
improvements and experimental studies of both efficiency and safety need be examined 
comprehensively before their clinical use. 
 
GENE EDITING 
For the treatment of dominant disease, a new approach has emerged that enables 
investigators to directly manipulate genes both in vitro and in vivo. This principal 
technology – usually referred to as “gene editing” or “genome editing” – is based on the 
application of engineered nucleases consist of sequence-specific, DNA-binding 
compartment fused to a DNA cleavage module128, 129. These chimeric nucleases enable 
reliable and precise genetic modifications by introducing double-strand breaks (DSBs) on 
DNA at a designated site in the genome that can potentially stimulate the cellular DNA 
repair mechanisms, including non-homologous end joining (NHEJ) and homology-directed 
repair (HDR)128, 129(Fig. 3). The versatility of this technology is enabled by the 
programmability of the DNA-binding ability that are obtained from zinc-finger (ZFN) and 
transcription activator-like effector (TALENs) proteins. In addition to those two 
technologies, investigators have also successfully developed a more efficient system using 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), which is 
a prokaryotic immune system that confers adaptive resistance to foreign genetic matters 




ZFNs were the first of the “genome editing” nucleases used in research. Zinc 
fingers are the most well-known DNA binding domain existed in eukaryotes. They typically 
are modules consist of around thirty amino acids that interact with nucleotide triplets. 
ZNFs have been engineered to recognize all of the 64 possible trinucleotide 
combinations128, 129, 133. By stringing different zinc finger moieties, it is feasible to use ZNFs 
specifically target any specific sequence of DNA triplets. Each ZNF can recognize 3-6 
nucleotide triplets. Because these nucleases can only function as dimers, pairs of ZNFs are 
necessary to carry out specifically targeting (one ZFN to recognize the sequence upstream 
and the other to recognize the downstream sequence of the site to be modified). 
 
 




TALENs, on the other hand, is similar to ZNFs in that they use DNA binding motifs 
to guide the same non-specific endonuclease to cleave the DNA at a specific site in the 
genome133. However, instead of recognizing DNA triplets, each TALENs domain recognizes 
a single nucleotide. The interactions between the DNA binding domains and their target 
nucleotides are less sophisticated than those between ZNFs and their target 








CRISPR is the latest but most exciting development in genome editing technology. 
CRISPR are RNA-based prokaryotic defense mechanisms evolved to recognize and exclude 
foreign DNA from invading bacteriophages137. CRISPR consists of an endonuclease called 
“Cas” that is directed to cleave a target sequence by a guide RNA (gRNA)133(Fig. 4). Both 
the Cas endonuclease and the gRNA are naturally encoded in the bacterial genome, and 
this system can act synergistically to cleave any desired target site by engineering the 
sequence of the gRNA. 
Just like the ZNF and TALEN systems, the CRISPR system can also be used to create 
double-strand break at a specific site. This break can then induce the occurrence of non-
homologous end joining or homology-directed repair for the creation of desired mutation 
or gene correction130, 133.  
The CRISPR system provides several advantages over the ZNF and TALEN systems. 
First, as mentioned, it is restively easier to make the target design. Because the target 
specificity totally depends on RNA/DNA complex formation instead of protein/DNA 
recognition, gRNAs can be designed readily in a cost-efficient way to target almost any 
sequence in the genome130, 133. Second, CRISPR has a higher efficiency among all three 
gene editing tools. DNA manipulation can be created by direct injection of Cas9 protein 
and gRNAs into developing mouse embryos. This method eliminates the laborious 
processes of transfecting and screening mouse ES cells that are required to generate 
targeted mutant mice using traditional homologous recombination techniques130, 133.  
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And the last, CRISPR is possible to be multiplexed. Several mutations can be 
introduced in one or multiple genes at the same time by a single injection with multiple 
gRNAs. 
All three gene editing technologies offer researchers with handy methods to 
develop mutant mouse or cell model for the studying of human disease, which were 
previously difficult to create by traditional gene targeting methods138. However, all these 
three methods has some potential drawbacks. The most critical issue is off-target 
effect138-140. Unwanted mutation can be introduced at non-specific loci with similar, but 
not identical sequence to the target sites. These odd-targeting effects can be difficult to 
identify and usually require scanning of the whole genome for searching these mutations 
(usually by whole genome sequencing). Another disadvantage is the difficulty of delivery, 
especially for the purpose of gene therapy. For instance, the most widely-used Cas9, the 
SpCas9 is around 4 kb. For the packaging of the transgenes comprising Cas9 and 
associated gRNA can barely fit into an AAV vector. Efficient expression of those large 
nucleases for gene editing requires further development and improvement. 
Despite these drawbacks, ZNFs, TALENs and especially the CRISPR/Cas systems are 
still so far the most powerful tools for manipulating the genomes. It can be expected 






ADENO-ASSOCIATED VIRAL VECTORS  
Most experiments utilize an adeno-associated virus (AAV) as the new standard for 
retinal gene therapy24, 81-84. AAV is a non-enveloped, icosahedral-shaped member of the 
parvoviridae family; thus, it is a small virus with a virion about 25nm in diameter 
composed entirely of protein and DNA85, 86. This fact means that AAV vectors are merely 
capable of packaging approximately 4.7 kb of DNA85, 87. Hence, both the gene of interest 
and the promoter must fit this space requirement, making it a limiting factor of using AAV.  
The AAV2 genome is the most widely studied, and is constituted of linear, single-
stranded DNA containing 4679 nucleotides24, 81-88. The AAV genome is composed of three 
open reading frames (ORFs) flanked by inverted terminal repeat (ITR) sequences that act 
as the viral origin of replication (ori) and packaging signal81, 82, 85. AAV2 carries one ORF 
with two genes that encode four non-structural replication proteins (Rep40, Rep52, 
Rep68, and Rep78) and another ORF with three 60-mer capsid proteins (VP1, VP2, and 
VP3), together with the third ORF containing an assembly-activating protein which is 
flanked on each side by 145 base-pair ITRs85, 89, 90. The two larger replication proteins, 
Rep68 and Rep78, play a role in many aspects of the AAV2 life cycle, including 
transcription, replication of the viral DNA, and site-specific integration into human 
chromosome 19. The other two smaller replication proteins are used for packaging of the 
DNA into the viral capsid85, 91. The three capsid proteins have different translational start 
sites, even though they come from the same gene. 
There are eleven known naturally occurring serotypes for AAV, and over 100 
artificial variants86. The capsid proteins can be found in distinctive configurations for the 
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various AAV serotypes, AAV1-9, however it is believed that they are found in a ratio of 
1:1:10 VP1:VP2:VP385, 92, 93. These AAV capsid proteins determine its tropism (the ability 
to transduce specific cell types), permitting both cell surface receptor binding and the 
entry into the host cell nucleus86. The mechanism by which AAV enters a host cell is 
through phagocytosis by receptor-mediated endocytosis85, 94. There has been in vivo 
evidence supporting the use of both clathrin-coated pits and clathrin-independent 
carriers/glycosylphosphatidylinositol-anchored protein-enriched endosomal 
compartments for this process86. The mechanism of cell entry for each AAV serotype 
remains to be studied. 
After entry into the host cell, the capsid then leaves the endosome and gets into 
the nucleus. There has been evidence supporting both uncoating before nuclear entry, 
and uncoating after nuclear entry, and the exact timing of the uncoating of the capsid is 
yet to be clarified86. Nevertheless, the localization to the host cell nucleus occurs via 
capsid protein VP1, which contains a phospholipase domain that allows for the escape 
from the endosome85, 95. The N-termini of capsid proteins VP1 and VP2, which comprise 
nuclear localization signals, then direct the capsid to the host cell nucleus85, 96. The 
genome is released in the nucleus by the capsids and converted to double-stranded DNA 
by means of the replication proteins and host cellular DNA synthesis machinery85, 86, 97. 
Without the presence of a helper virus, AAV enters a latent life-cycle and the DNA 
is retained in a circular episomal form in the nucleus, otherwise integrated into the human 
chromosome 19, at a specific locus termed AAVS185, 98-101. Due to the fact that AAV 
serotypes contain modifications in the capsid proteins, each serotype has diverse tropism 
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for different target cells and tissues. Hence, recombinant AAV vectors utilized in gene 
therapy have to be selected for their tropism to efficiently and effectively transduce the 
cell-type of interest. For instance, AAV1 was found to more effectively transduce muscle 
cells when compared to AAV2, and AAV5 to more effectively transduce the central 
nervous system in comparison to AAV2. These tissues are highly targeted by different 
serotype to treat disease, making these AAV serotypes thrilling for the potential of 
introducing gene therapy vectors to those tissues that were previously difficult for 
clinicians and researchers to treat with therapeutic agents. 
The recombinant   AAV used as a packaging vector for gene therapy has its viral 
compartments, the replication and capsid proteins, removed from the   gene therapy virus. 
This makes the AAV non-pathogenic and theoretically safe for human clinical trials. The 
ITRs that flank the AAV genome are the only cis-acting elements in the AAV that are 
required for the genome replication, integration, and packaging of the capsid85. Hence, 
the replication and capsid proteins flanked by the ITR sites are replaced with the promoter 
and gene of interest for gene therapy. The replication and capsid proteins are then 
expressed in trans in a separate plasmid that lacks the ITRs, preventing the formation of 
a viral AAV particle after delivery. The recombinant AAV vector is feasible transduce both 
dividing and non-dividing cells with stable transgene expression without the presence of 
a helper virus in post-mitotic tissue86. These features make recombinant AAV a 
remarkable tool for gene therapy studies85 and trials for human diseases. 
However, science did not stop developing the AAV gene therapy vector system at 
this point. These recombinant AAV particles have been made more efficient using 
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numerous technological advances. One of these is the creation of self-complementary (sc) 
AAV vectors. In scAAV vectors, the terminal resolution site of one ITR has been removed, 
preventing the initiation of replication at this end85, 102. This creates a single-stranded, 
inverted repeat viral genome with one wild-type ITR at one end and a mutated ITR in the 
center. This allows for the vector genome to fold after uncoating and creates a double-
stranded, or self-complementary, genome.  
These scAAVs, hence, do not require the host cell DNA synthesis machinery 
synthesize single-stranded DNA to double-stranded DNA before transcription and 
translation; they are incorporated with their DNA in the double-stranded form. There is a 
faster gene expression using scAAV vectors in comparison to recombinant AAV vectors, 
due to this skipped step in DNA synthesis, and these scAAV vectors have been found 
capable to transduce different cell types that previously did not express transgenes using 
the recombinant, single-stranded AAV vectors85. However, these vectors are almost half 
the size (around 2.5 kb) of the recombinant AAVs, making them more restricting than 
recombinant AAV vectors due to DNA packaging constraints. 
Scientists found another method in which to strengthen the recombinant AAV 
vectors. They created hybrid AAVs, in a procedure called “pseudotyping,” to create 
vectors that target specific cell types with greater efficiency. At the time, research had 
observed AAV gene therapy viruses to be restricted in regards to certain cells of interest. 
For instance, AAV2 vectors were the most carefully studied, and AAV2 vectors were used 
to efficiently transduce RPE cells in many animal models for several years. This made them 
an appealing therapeutic agent due to the fact they could potentially have a long-term 
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effect after a single administration of the vector into human patients103. Even though 
AAV2 has been proven more effective for transduction of the RPE cells, it was not clearly 
shown to have a long-lasting effect on the photoreceptor cells104, 105.  
Hence, pseudotyping became a method to create AAV vectors that would more 
efficiently transduce the photoreceptor cells and other specific types which were not 
specifically targeted by AAV2. Pseudotyping relies on the recombinant AAV2 plasmid 
(with the ITRs from AAV2) and packages it into a capsid derived from another AAV 
serotype. This design puts the AAV2 replication genes downstream of the p19 promoter 
with the respective replication genes of another serotype followed after the promoter 
sequence85, 106. These AAV vectors are named after the serotype 2 replication proteins 
(genome) and the serotype from the AAV serotype capsid proteins. For instance, a wild-
type AAV2 capsid vector is typically written as “AAV2/2,” while the pseudotyped AAV with 
serotype 8 capsid for the gene therapy vector used in this study is written as “AAV2/8.” 
This pseudotyping procedure grants advantages in the usage of AAVs in regards to 
improving gene therapy. For instance, the same vector genome, from AAV2, when 
packaged into the different AAV serotype capsids, the only difference between the 
pseudotyped AAV vectors is their viral capsid. This enables research to analyze each AAV 
serotypes in vivo and precisely determine its transgene expression efficiency and tissue 
tropism85, 106, 107. The commonly used AAV serotype, AAV2/2, features a gradual increase 
in transgene expression over time, reaching plateau at approximately 2-4 months post-
injection. In contrast, AAV2/1 or AAV2/5 vectors were able to initiate transgene 
expression much sooner, usually 3-4 days post-injection103.  
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Besides the early gene expression feature, the different AAV serotypes and 
pseudotyped vectors were found to have diverse tropism, especially to different retinal 
cells. For instance, AAV2/4 is more efficiently to target the RPE cells than AAV2/2 or 
AAV2/5 when targeting both RPE and photoreceptors, while AAV2/8 has been found to 
have best efficiency targeting all the retinal cells (including photoreceptors, the RPE cells 
and the rest of the cells of the neural retina24, 81, 103, 104, 106, 107. Thus, researchers can 
choose the AAV gene therapy vector based on the desired cell type that they are 
interested in targeting, and appropriate time frame they would like the transgene 
expression to initiate in the cell.  
 
 
Figure 5. Subretinal and intravitreal injection. 
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For the drug delivery in retina, there are typically two main routes for viral 
administration by injection (Fig. 5): intravitreal and subretinal81, 92, 103. Intravitreal 
injection introduces the AAV vector within the vitreous space of the eye, which permits 
viral deliver to the retinal ganglion cells or Müller glial cells. It is an ideal route for anti-
angiogenic therapies for conditions such as diabetic retinopathy. Intravitreal injections is 
now standard practice by most ophthalmic clinicians81, 92, 103. Currently, researchers are 
looking into develop AAV vectors that could pass through the complex retinal cell layers 
after intravitreal delivery108. Unfortunately, currently there is no AAV serotype that can 
efficiently transduce the RPE or photoreceptor cells through intravitreal injection.  
Subretinal injections is more optimal for the targeting of the RPE or photoreceptor 
cells. This method introduces the virus into the interspace between the RPE and 
photoreceptors, creating a temporary cavity with retinal detachment termed the 
“subretinal bleb.” This retinal detachment will naturally disappear after the diffusion of 
the viral agent92, 103.  
Subretinal injections are clinically used for human patients, but unlike intravitreal 
injections, this technique requires an invasive surgical procedure. In humans, the surgical 
procedure involves a partial vitrectomy to increase in the volume of the AAV being 
injected, and also to balance intraocular pressure. However, it is not possible to carry out 
the vitrectomy procedure in mouse model. It is still possible to perform the subretinal 
injection on mice, but it requires careful skill and practice. Due to the small size of mouse 
eye ball, subretinal injection on mice usually has a successful rate at only 20%. In addition, 
the mouse eye has a much larger lens when comparing to humans. The lens must be 
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avoided during the surgical procedure otherwise can lead to cataract formation and a loss 
of vision. Therefore, for both mice and humans, the subretinal injection surgical 
procedure is typically more challenging than ordinary intravitreal injection and has a 
higher rate for surgical morbidities92, 103. However, it is the best method for achieving 
efficient transduction on RPE and photoreceptor cells. Injections of the current 
established AAV serotypes into the subretinal space are capable to transduce the RPE 
cells with 100% efficiency in the location surrounding the subretinal bleb, and 
approximately 20-40% transduction efficiency of the photoreceptor cells in the area 
within the subretinal bleb, depending on the used AAV serotype for transgene delivery92, 
103. 
Lastly, once the correct gene therapy vector has been selected, the method of 
administration determined, the clinician must then be concerned about safety issue. 
Immune response to the viral injections has become a concern following initial gene 
therapy trials on human patients. The gene therapy treatment itself may be successful, 
but when it comes to the adverse side effects, especially in young children, could 
potentially resulted in unwanted effects87, 109, 110. 
For gene therapy utilizing AAV viruses, since AAVs are generally non-pathogenic, 
safety concerns mainly only arise from whether or not the host will produce neutralizing 
antibodies to block virus transduction. Though neutralizing antibodies against AAV2 have 
been observed after the first injection of a gene therapy virus, but repeated ocular 
administration of the viral vectors in animal models does not arise obvious safe concern92, 
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111. This could possibly accredited to retinal-blood barrier of the RPE and choroid, which 
makes the eye immune-privileged comparing other organs.  
 
GENE THERAPY CLINICAL TRIALS  
At present, there is no clinical trial for ADRP. There are currently several human 
clinical trials using AAV gene therapy in the eye for LCA disease, which is a recessive 
blinding disorder caused by a mutation in RPE65 (NCT00999609; NCT00821340; 
NCT01496040; NCT00481546). RPE65 is an isomerase in the visual cycle which converts 
all-trans retinyl esters to 11-cis retinal within the RPE to make 11-cis retinal available for 
photoreceptor OS to make a molecule of rhodopsin 13, 24, 81, 112. RPE65 mutations account 
for around 5-10% of all LCA cases, and disease symptoms are present at birth or no later 
than the first months of life24, 81, 113-116. Diagnosis of LCA is confirmed by ERG and pupillary 
responses to light85, 113-115.  
The LCA clinical trial was initially using a canine model with a mutation in RPE65. 
This model lacks functional RPE65 protein which is then supplemented by the delivery of 
the RPE65 cDNA packaged within the AAV2/2 virus. This gene replacement was 
alsoadministrated by injection of this viral vector into the subretinal space of the canine 
eye. Visual function was found restored in this canine model and has been sustained for 
more 9 years at this time13, 24, 85, 103, 117-120.  
The LCA human clinical trial began in 2007. The LCA Phase I clinical trial consisted 
of three patients between 19-26 years of age85. They all received a low dose injection of 
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the gene therapy virus in the eye for the estimation whether or not the viral gene therapy 
vector was safe in human. All three patients displayed improved vision in dim light 
settings in around two weeks after administration. Pupillary responses to light were also 
ameliorated in each of the three patient eyes injected with the gene therapy virus, 
becoming at least three times more sensitive to light than pre-treatment response. The 
efficacy of this gene therapy treatment was able to persist through the 1.5 year follow-up 
time-point 85, 121.  
The 1.5 year data presented two essential benefits to AAV-mediated gene therapy 
research field. First, this trial confirmed that the transgene expression following AAV 
delivery is consistent in human patients over time and sustainable in the host cells. 
Second, the AAV2-mediated gene therapy to the retina does not cause a harmful immune 
response such as cytotoxic T-cell response in the patients85. However, there were still 
unexpected findings from the clinical trials. None of the patients had improved ERGs 
response, in contrast to the canine models after gene therapy. This result suggests a 
possibility of unstoppable degeneration in the patients after treatment.  
In addition to the eye, AAV-mediated gene therapy treatments have also been 
used for other human genetic diseases. Hemophilia B, which features an X-linked bleeding 
disorder caused by the deficiency of clotting Factor IX, has three independent phase I 
clinical trials using AAV285. This disease is a good target for gene therapy for monogenic 
cause, and as little as 1% increase in the physiological levels is able to improve the severe 
bleeding phenotype in human patients. The therapeutic effect has already been observed 
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after a single administration of AAV2/2 through muscle or liver injection on murine and 
canine models of hemophilia B85, 122-127.  
It is critical for scientists to determine which patients may benefit from gene 
therapy. For example, P23H mutation in RHO are the most common RP in North America30. 
Therefore, there are many potential recipients who would be able to benefit from gene 
therapy specifically targeting this mutation. However, the disease phenotype resulted 
from this mutation is relative mild, and patient’s vision remains acceptable until old age. 
In contrast, other more severe mutations such as RHOC110R mutation or mutations within 
the PDE6α or β subunit could serve as a better model30. Patients with these mutations 
typically has early onset of disease in childhood. One limitation for the treatment of these 
patients would be the ability to diagnose these patients early enough to provide the 









CHAPTER 2: ESTABLISHMENT OF CRISPR-MEDIATED GENE ABLATION  
I. INTRODUCTION 
Retinitis pigmentosa is an inherited disease characterized by 
bilateral degeneration of rod-cone photoreceptors, which ultimately leads to night 
blindness and progressive visual impairment141. The rod-specific light-sensitive pigment, 
rhodopsin (RHO), is a specialized G-protein coupled receptor that initiates 
phototransduction. Thus far, approximately 150 different mutations have been found in 
RHO, which account for 30% of dominant RP cases and 15% of all inherited retinal 
dystrophies. Two strategies are most commonly applied to treat autosomal dominant (ad) 
retinitis pigmentosa: expression of the wild-type RHO protein and elimination of the 
mutant protein142-144. The former strategy can be achieved by gene replacement, a well-
established technology that uses viral vectors to introduce wild-type protein into cells of 
interest. While gene replacement itself may partially offset the adverse effects of 
dominant-negative proteins, it is powerless when used to counteract gain-of-function 
mutants142, 143. The latter strategy, elimination of the mutant protein, could eradicate the 
bent causing the disease phenotype. However, this method also presents with its own set 
of challenging issues. For example, mRNA knockdown of pathologically mutant genes 
using either short interfering RNAs (siRNAs) or ribozymes only partially and transiently 
decreases mutant protein levels145-147. Moreover, these tools often exhibit poor 
specificity when distinguishing between mutant versus wild-type alleles due to the fact 
that most of the mutations in RHO are single-nucleotide mutations.  
43 
 
The new emerging gene ablation tool, clustered regularly interspaced short 
palindromic repeats (CRISPR), which involves the collaboration between Cas9 and a single 
guide RNA (abbreviated henceforth as “CRISPRs”), has been proposed to specifically 
destroy the mutant gene by targeting the unique mutation148, 149. Traditionally, this gene 
ablation is performed by introducing a frameshifting nucleotide insertion or deletion 
(InDel) concomitantly with non-homologous end joining (NHEJ) at the CRISPRs-targeted 
site150, 151. However, the drawbacks of CRISPRs are significant. For one, not every mutation 
is unique enough for CRISPRs, which involves highly allele-specific designs. Moreover, 
efficiency is compromised by the fact that most NHEJ results in precise ligation rather 
than the desired frameshifting InDels152, 153. Last but not least, the costs of CRISPRs drug 
development are prohibitive given that the specificity of the guide RNA (gRNA) mandates 
separate clinical trials for each mutation, regardless of whether or not the mutations 
reside in the same gene142. 
To address these issues, we present a two-pronged “ablate-and-replace” strategy 
that (1) destroys the expression of all endogenous chromosomal Rho genes in a mutation-
independent manner using an improved, mutation-independent CRISPR/Cas9-based 
gene ablation technique and (2) enables expression of wild-type protein through 
exogenous cDNA (Fig. 6).  For gene ablation, we utilize Cas9 and double gRNAs 
(abbreviated henceforth as “CRISPRd”) to create two double-strand breaks and, therefore, 
a large deletion that permanently destroys the targeted gene on both of the alleles. We 
combine this gene-ablation tool with gene replacement to deliver wild-type cDNA that 
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compensates for the lost endogenous RHO protein. We hypothesize that this toolset can 
be used to treat adRP caused by different types of Rho mutations. 
 
 











To develop our CRISPRd gene excision tools, we first designed two gRNAs to target 
sequences in exon 1 of mouse Rho, leading to double-strand breaks 27 base pairs (bp) 




Figure 7. Illustration of double (CRISPRd) or single (CRISPRs) gRNA strategies to 
specifically ablate mouse Rho exon 1. 
 
Of note, both sites are relatively void of pathogenic mutations and single 
nucleotide polymorphisms. To compare the gene-ablating efficiency of CRISPRd vs 
CRISPRs in vitro, we cloned gRNA1+2 or gRNA2 into respective modified pX459 vectors 







Figure 8. Modified pX459 vectors for CRISPRd and CRISPRs. 
 
After two weeks of puromycin selection, the total genomic DNA was extracted for 
PCR. We expected that the CRISPRd and CRISPRs plasmids would respectively yield 5 and 
2 gene editing scenarios (Fig. 9, type 1~5 and type 1~2), which would generate three gene 
expression outcomes: (1) normal/unaffected mouse Rho (mRho) expression resulting 
from either no editing or non-destructive NHEJ; (2) no mRho expression resulting from 
gene truncation or destructive NHEJ (frameshift); and (3) compromised expression 















We first examined genomic PCR products to grossly confirm genetic outcomes (Fig. 
10).  
CRISPRd (gRNA1+2) yielded a prominent 400-bp band that represents truncated 
mRho exon 1 (Fig. 9, row 5) and a minor 750-bp band that represents parental, full-length 
exon 1 (Fig. 9, row 1). In contrast, CRISPRs (using only gRNA2) generated just the 750-bp 
band. To more precisely gauge genetic outcomes and quantify their respective 










Figure 10. Validation of mRho exon 1 truncation. 3T3 cells were transfected with CRISPRd 
or CRISPRs plasmid (Fig. 8), and then submitted to 2 weeks of puromycin selection 
followed by genomic PCR (primers indicated in Fig. 7). 
 
With CRISPRs, only 60.0 ± 9.9 % of the mRho gene was ablated due to destructive 
NHEJ resulting in frameshift mutations; in the remaining 40.0 ± 9.9 % of the gene that was 
not ablated, exon 1 was either intact (24.4%) or had in-frame mutations (15.6%) (Fig. 9 
and 11 lower part). With CRISPRd, more than 90 ± 7.8 % of the mRho gene was ablated 
due to truncation (62.3%) or NHEJ-induced frameshift at the gRNA2 targeting site (28.3%) 
(Fig. 9 and 11 upper part). Similarly, with CRISPRd, only 5.7% of amplicons contained 
intact mRho sequence compared to 24% with CRISPRs, even after two weeks of 











Figure 11. Schematic summary of the basic outcomes produced by CRISPRd- and 

















III.  DISCUSSION 
Our experiments provide evidence for the superiority of CRISPRd over CRISPRs in 
many regards. Consistent with previous findings154-157, our Dideoxy-Sanger sequencing 
results showed that the induction rate of CRISPRd is higher than that of CRISPRs. These 
differences in outcome are most likely due to the fact that less than 0.1% of the NHEJ 
generates InDel158. The production of destructive NHEJ may largely rely on repeated 
cutting. CRISPRd-induced truncation, on the other hand, is more independent of the error 
rate and only depends on the occurrence rate of NHEJ. Also, unlike homology-dependent 
repair, NHEJ is active in both dividing cells and non-dividing cells; thus, there is no 
limitation on cell cycle for our strategy159. In addition, our results also demonstrate that 
CRISPRd can minimize the creation of secondary, in-frame mutations induced by NHEJ 
(CRISPRd 1.9% vs. CRISPRs 15.6%), which is essential for preventing the creation of more 









CHAPTER 3: ESTABLISHMENT OF AAV VECTORS AND SUBRETINAL INJECTION OF GENE 
THERAPY VECTORS  
I. INTRODUCTION  
AAV vector has a packing capacity at around 4.5 kb, including ITR sequences. The 
SpCas9 cDNA is about 4.2kb98, 102, 103, 106. To deliver the components for CRISPRd and the 
gene replacement hRHO cDNA, dual AAV vector system are necessary to encapsulate all 
the elements. The first AAV which express SpCas9 is driven by sCMV promoter, which is 
173 bp long. The poly-A tail is a 49 bp long SV40 SPA sequence. The second virus is 
designed to express two gRNAs and the hRHO gene replacement. The gRNA is driven by 
U6 promoter and the whole gRNA expressing cassette (including the gRNA scaffold) is 346 
bp long. And hRHO gene replacement sequence is placed next to the gRNA cassettes. The 
length of hRHO cDNA itself is 1047 bp. The promoter used to drive hRHO cDNA expression 









II. RESULTS  
To maximize the expression of hRHO gene replacement in the transduced 
photoreceptor, we truncated mRho promoter region to different lengths. From the 




Figure 12. Schematic design of primers to generate truncated Rho promoter with 
different length. 
 
Promoter with different length was cloned into pCDNA3.1 vector with EGFP cDNA 
as a reporter for gene expression. These plasmids were transduced into HEK293 cells for 
the evaluation of promoter strength. Since HEK293 cell line does not normally express 
transcription factors of RHO gene, a tripartite plasmid expressing human transcription 
factors NRL, CRX and NR2E3 (Fig. 13) was made and co-transfected into HEK293 along 







Figure 13. Plasmid expressing transcription factors CRX, NRL and NR2E3.  
 
 
The HEK293 culture was incubated for 48 hours for protein expression before the 
fluorescence microscopy analysis. No any fluorescence was detected in transcription 
factors alone group (Fig 14, left column). Very little fluorescence was observed when 
using 4.2 kb Rho promoter to drive EGFP on HEK293 cells without the co-transfection of 
transcription factors (Fig 14, central column). As expected, when co-transfect both 
plasmids together into the cells, the fluorescence increased in intensity and quantity (Fig 





Figure 14. Testing of Rho promoter reporter. HEK293 cells were transfected with plasmid 
CMV-NRL-CRX-NR2E3, pRho-EGFP or both. The bright filed and fluorescence were 
captured after 24 hours of transfection. 
 
 
Flow cytometry was used to precisely compare the expression of fluorescence of 
EGFP driven by different length of the mRho promoters. Surprisingly, all the groups 
expressed similar florescence intensity (Fi. 15), no significant difference was detected in 
median and geometric mean values. Enhance, for the establishment of the gRNAs + gene 






Figure 15. Different Rho promoters exhibit similar driving efficiency. FACS was used to 
measure the fluorescence emitted by HEK293 cells transfected with GFP-expressing 
plasmid driven by different lengths of Rho promoter. 
 
 
To test our combination CRISPRd gene ablate-and-replace strategy in vivo, all 
components were cloned into two AAV 2/8 vectors (Fig. 16). Codon-optimized Cas9 cDNA 
driven by the sCMV promoter was packaged into one vector (AAV-Cas9), while the dual 
gRNA expression cassettes and human RHO (hRHO) cDNA (for xenogeneic gene 
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replacement) driven by a 2.2 kb mRho promoter were cloned into another (AAV-GR, 




Figure 16. Schematic of experimental (AAVs-Cas9+GR) and control (AAVs-Cas9+SR) 
AAV2/8 vector pairs. 
 
 
Thus, gene ablation could only occur in cells that took up both vectors (AAV-Cas9 
+ AAV-GR) while gene replacement could occur in any rod photoreceptors that took up 
just the hRHO cDNA-containing vector (AAV-GR). Since overexpression of wild-type RHO 
can, by itself, might slightly improve vision in hRHOP23H transgenic mice144, we designed a 
control AAV vector (AAV-SR, stands for scrambled gRNA and hRHO), in which both gRNAs 
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are replaced with scrambled sequences (Fig. 16); thus, in rods transfected with the AAVs-
Cas9+SR vector pair, CRISPRd does not function, but xenogeneic gene replacement does 
(Fig. 17). Both gRNA1 and 2 were designed to specifically target mRho, not hRHO (Fig. 18).  
 
 
Figure 17. Conventional gene replacement therapy vs CRISPRd plus gene replacement, 













Figure 18. The gRNAs sequences, their targeting sites on mRho and the corresponding 
sites on hRHO. The two gRNA have 12 and 4 mismatches on hRHO, respectively. 
 
 
The hRHO gene replacement was codon-modified by silent mutations to maximize 
the difference against gRNA targeting. Indeed, in an in vitro, cell-free assay, gRNA1 or 




Figure 19. Representative data of in vitro SpCas9/gRNA cutting. In a cell-free assay, 
mRho vs hRHO DNA template was mixed with recombinant SpCas9 protein and a single 




To validate that AAVs-Cas9+GR can mediate CRISPRd gene ablation in vivo, right 
eyes of wild-type C57BL/6J adult mice received a single, 1.5-microliter subretinal injection 
of AAVs-Cas9+GR (Fig. 20); as required by animal protocol, left eyes were uninjected, 
negative controls. Two weeks after the injection, retinae were collected for analysis.  
 
Figure 20. Experimental scheme and timeline for subretinal injection of dual AAV 
vectors in right eyes of wild-type C57BL/6J mice. (using a unique, posterior approach) 
 
 
Cas9 immunostaining of whole, flat-mount retinae revealed AAV-Cas9 







Figure 21. Representative data of Cas9-immunostaining in retinal flat mount. 14 days 
after Cas9+GR subretinal injection (left figure), the retinas were collected and stained for 
anti-Cas9 antibogy (central figure, n=3). Image was assembled from multiple pictures. The 
transduced percentage was estimated by the fluorescent area/total retina area (right 
figure). 
 
Genomic PCR analysis revealed the 400-bp truncated and 750-bp parental mRho 




Figure 22. Representative data of PCR analysis of retinal genomic DNA from AAVs-





Dideoxy-Sanger sequencing analysis of the 400-bp PCR amplicon confirmed that it 
was, in fact, truncated mRho exon 1, and that the large deletion had removed the start 
codon (Fig. 23). These data suggest that our CRISPRd dual-vector tool truncates mRho 





Figure 23. Representative data of mRho gene ablation validated by Sanger sequencing 




We further determined if this in vivo AAVs-Cas9+GR-mediated gene ablation leads 
to decreased endogenous mRho levels in photoreceptors. Since there does not exist an 
antibody that can distinguish mRHO from hRHO protein, we extracted total retinal mRNA 






Figure 24. Gene ablation and replacement are co-localized in rod photoreceptors in vivo. 
A, Total retinal mRNA from injected eyes was analyzed by qPCR for mRho expression; 
values were normalized to Pde6g, a rod photoreceptor housekeeping gene, and control, 
AAVs-Cas9+SR were defined as 100%. Values are presented as mean ± s.d. Unpaired two-
sided t-test was used for the statistics (*, p<0.05). B, RT-PCR of total mRNA isolated from 
whole retinas from two right eyes injected with AAVs-Cas9+GR and two uninjected fellow 
(left) eyes. C, Scatter plot of qPCR-derived dCt values of mRho and hRHO mRNA isolated 
from 11 whole retinas from 11 left eyes injected with AAVs-Cas9+GR. The trend line is 




Retinae treated with AAVs-Cas9+GR exhibited a 25% decrease in mRho mRNA 
compared to AAVs-Cas9+SR (Fig. 24A), thus demonstrating that gene ablation is occurring 
in rod cells transduced with AAVs-Cas9+GR. In addition, xenogeneic hRHO mRNA 
expression was clearly detectable in the injected eyes, indicating the transduction of AAV-
GR into rod cells (Fig. 24B). We also found that mRho mRNA levels decreased as the hRHO 
mRNA increased based on a scatter plot of qPCR dCt values (Fig. 24C). This negative 
correlation (coefficient r = -0.69) between mRho and hRHO levels indicates that gene 
ablation consistently occurs in proportion to gene replacement, as our dual vector system 











III. DISCUSSION  
In this study, we compared the transgene driving efficiency of mRho promoters 
with different lengths. From the 4.2 kb to the shortest 0.5 kb prmoter (with 0.5 kb 
descending), we found there is no significant difference based the florescence of EGFP 
reporter. This result implies the critical cis-element of promoter resides with in the region 
close to the transcription start site. This result may also indicate that it is unnecessary to 
include excessive upper stream sequence of mRho promoter to reach maximum driving 
efficiency.  
To encapsulate all the gene ablation and gene replacement components, dual AAV 
system is required to provide necessary capacity. However, to achieve gene ablation and 
gene replacement altogether, the two viruses have to be transduced into the same cell. 
It has already been reported that injecting reporter AAVs expressing GFP and RFP to the 
mouse retina can efficiently achieve high level of co-transduction143. In our study, we 
further confirmed if this co-transduction allows gene ablation and gene replacement 
taken place together. By the negative correlation between mRho and hRHO, we 
concluded the transduced retina cells receive both viruses. (Fig. 25, upper set). Because 
if AAV-Cas9 and AAV-GR were not received by the same cell, we expect that the when 






Figure 25. Schematic of two different AAVs distribution scenarios. Upper, if the two 
viruses were transduced into the same cell while the other cell receive no virus, the mRho 
level of the former cell should reduce and hRHO level should increase while nothing 
changes in the later cell. Lower, if the two viruses were received by two separate cells, 
the mRho level in both cells should not change. Only the hRHO level should increase in 







CHAPTER 4: TEST OF ABLATE-AND-REPLACE VECTORS IN PRE-CLINICAL MODELS OF 
RETINITIS PIGMENTOSA  
I. INTRODUCTION 
The aim for this experiment is to test if our dual AAV, ablate-and-replace 
combination system has therapeutic efficacy in dominant retinal degenerative disorders, 
and also whether our dual vectors act in a mutation-independent fashion. To do this, we 
chose two knock-in mouse models of human RP caused Rho mutations: P23H on exon 1 





















The P23H mutation, which causes dominant-negative and gain-of-function 
phenotypes such as protein retention in the Golgi apparatus and the unfolded protein 
response39, 142, is the most prevalent hRHO mutation in North America. The D190N 
mutation compromises RHO thermal stability and, therefore, leads to a gain-of-function 
increase in dark noise and slow yet progressive retinal degeneration160-163. For these two 
mutations, we tested one homozygote (RhoP23H/P23H) and two heterozygote (RhoP23H/+ and 
RhoD190N/+) models, since nearly all RHO mutant patients are heterozygous. Single 
subretinal injections of AAVs-Cas9+GR, AAVs-Cas9+SR or PBS were performed between 
postnatal days 1 and 3 (Fig. 27); left eyes were not injected. At P21 or later, retinal 
function was assessed by electroretinography (ERG), and then eyes were dissected and 
processed for histological analysis (Fig. 27).  
ERG responses are characterized by a photoreceptor-mediated a-wave (negative 
deflection) followed by an inner retina-mediated b-wave (positive deflection). 
Importantly, we controlled for mouse-to-mouse variation by dividing a- and b-wave 
amplitudes for the injected (right) eyes by their respective amplitude for the uninjected 






Figure 27. Experimental and disease progression timelines. Right eyes received a single 
1.5-microliter subretinal injection of AAVs-Cas9+GR, AAVs-Cas9+SR or PBS between P1 
and P3; left, fellow eyes were uninjected. On the indicated days, ERGs were performed 
and tissue prepared for histology. Approximate time windows for rod-driven 









Figure 28. Therapeutic effect of RhoP23H/P23H mice. (A) H&E stained retinal sections of 
right (injected) eyes from P21 RhoP23H/P23H mice, which were injected with either AAVs-
Cas9+GR, AAVs-Cas9+SR or PBS; images were taken about 200 micrometer from the 
optic nerve. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, optic nuclear layer; 
RPE, retinal pigment epithelium. (B) Representative ERG traces of injected right eyes 
(green traces) and uninjected left, fellow eyes (red traces). Arrows, peaks of oscillatory 
potentials. (C) Percent change in ERG amplitudes. Each dot represents a b-wave 
amplitude for an injected, right eye that was normalized to the respective amplitude 
value of the uninjected fellow (left) eye. N values indicated on x axis; horizontal black 
lines, group means. Unpaired two-sided t-test was used for the statistics (*, p<0.05; **, 
p<0.01; *** p<0.001). In RhoP23H/P23H mice, only b-wave data are shown, because a-
waves are no longer detectable at P21. 
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To compare the number of surviving photoreceptors, thickness of the 
photoreceptor nuclei-containing outer nuclear layer (ONL) was approximated in 
histological images by counting the layers of photoreceptor nuclei (in wild-type mature 
retinae, ONL is 10-12 layers thick)160. RhoP23H/P23H homozygous mutant mice exhibit rapid 
and severe rod-driven retinal degeneration wherein rod cell death begins shortly after 
birth and results in complete loss of rods by P3043. In fact, in control retinae injected with 
PBS, the ONL was only 0 to 1 layer thick at P21 (Fig. 28A). In contrast, retinae transduced 
with AAVs-Cas9+GR or AAVs-Cas9+SR typically had ONLs that were 2-3 and 1-2 layers thick, 
respectively (Fig. 28A). Such improvement is also reflected in the outer segment (OS) 
thickness (Fig. 28D). Compared to the PBS control group, the OS length is 142% and 85% 
longer in the AAVs-Cas9+GR and AAVs-Cas9+SR group, respectively. These data are 
consistent with the notion that rescue is more efficacious with our AAVs-Cas9+GR ablate-
and-replace combination therapy compared to AAVs-Cas9+SR gene replacement. These 
qualitative structural data were validated by our quantitative ERG functional analysis (Fig. 
28B). Specifically, the mean b-wave amplitude for the AAVs-Cas9+GR group was 130% 
(relative to uninjected fellow eyes) versus 80% and 30% for the AAVs-Cas9+SR and PBS 
groups, respectively; these differences were highly significant (Fig. 28C). In addition, the 
peaks of oscillatory potentials of the AAVs-Cas9+GR group were more pronounced 
compared to either of the controls (Fig. 28B, arrows). These functional data suggest that 
neural signaling is significantly more robust in AAVs-Cas9+GR-treated retinae. The fact 
that all of the individual b-wave amplitudes in the PBS group and most of those in the 
AAVs-Cas9+SR group were less than 100% (i.e., less than uninjected left eyes) (Fig. 28C) is 
likely due to surgical trauma, which is inevitable in early postnatal mouse eyes. That the 
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AAVs-Cas9+GR group showed greater b-wave amplitudes than the uninjected eye despite 
surgical trauma is a reflection of the robustness of the intervention. Since subretinal 
injections induce only insignificant damage in human retinae, efficacy could be even more 
















Figure 29. Therapeutic effect of RhoP23H/+ mice. (A) H&E stained retinal sections of right 
(injected) eyes from P90 RhoP23H/+ mice, which were injected with either AAVs-Cas9+GR, 
AAVs-Cas9+SR or PBS; images were taken about 200 micrometer from the optic nerve. 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, optic nuclear layer; RPE, retinal 
pigment epithelium. (B) Representative ERG traces of injected right eyes (green traces) 
and uninjected left, fellow eyes (red traces). Arrows, peaks of oscillatory potentials. (C) 
Percent change in ERG amplitudes. Each dot represents an a- or b-wave amplitude for 
an injected, right eye that was normalized to the respective amplitude value of the 
uninjected fellow (left) eye. N values indicated on x axis; horizontal black lines, group 




In RhoP23H/+ and RhoD190N/+ mice, retinae were analyzed later than the RhoP23H/P23H 
mutant since rod-driven retinal degeneration is dramatically slower in these 
heterozygotes: rod death is complete by about 6 and 10 months, respectively (Fig. 27). In 
P90 RhoP23H/+ retinae, AAVs-Cas9+GR treatment yielded 6-8 layer thick ONLs compared to 
4-5 layers for AAVs-Cas9+SR treatment and 3-4 layers for PBS (Fig. 29A). The increase in 
OS thickness is more significant after AAVs-Cas9+GR treatment but is less efficacious in 
the AAVs-Cas9+SR group (Fig. 29D). In addition, AAVs-Cas9+GR-treatment significantly 
increased a- and b-wave amplitudes in RhoP23H/+ retinae compared to the AAVs-Cas9+SR 
and PBS controls (Fig. 29). Similarly, in P90 RhoD190N/+ mice, rescue by AAVs-Cas9+GR 
treatment was again statistically superior for both a- and b-waves (Fig. 30). These 
structural and functional efficacy data suggest that our ablate-and-replace combination, 
AAVs-Cas9+GR-treatment leads to significantly greater survival of functioning 
photoreceptors compared to AAVs-Cas9+SR-transduced retinae. The data also suggest 
that the treatment is mutation-independent. These results are consistent with our dual 








Figure 30. Therapeutic effect of RhoD190N/+ mice. (A) H&E stained retinal sections of 
right (injected) eyes from P90 RhoD190N/+ mice, which were injected with either AAVs-
Cas9+GR, AAVs-Cas9+SR or PBS; images were taken about 200 micrometer from the 
optic nerve. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, optic nuclear layer; 
RPE, retinal pigment epithelium. (B) Representative ERG traces of injected right eyes 
(green traces) and uninjected left, fellow eyes (red traces). Arrows, peaks of oscillatory 
potentials. (C) Percent change in ERG amplitudes. Each dot represents an a- or b-wave 
amplitude for an injected, right eye that was normalized to the respective amplitude 
value of the uninjected fellow (left) eye. N values indicated on x axis; horizontal black 
lines, group means. Unpaired two-sided t-test was used for the statistics (*, p<0.05; **, 




III. DISCUSSION  
Finding that gene replacement alone can only rescue the vision in homozygous 
mRhoP23H/P23H model but not the models of heterozygous P23H and D190N was 
unanticipated. This result is inconsistent with the previous findings on P23H and P347S 
mutation models143, 164. However, it is worth noting that all of the previous animal models 
were established by transgenic expression of mutant hRHO in mRHO-/-, mRHO+/+ or 
mRHO+/- backgrounds instead of the mutation knock-in method. Our findings suggest that 
selecting genetic models to simulate gene therapy of adRP in mice is pivotal for 
therapeutic development.  
Though AAV-delivered gene replacement is not integrating to the host genome, 
based on recent findings and clinical trials, the AAV-delivered gene replacement therapy 
of RPE65 has allowed the stable expression of retinal pigment epithelium (RPE) cells for 
3+ years in humans and 9+ years in canine models165-167. We expect that this gene 
replacement effect can last even longer in photoreceptor cells, because—unlike RPE 
cells—photoreceptor cells do not divide. However, further experimentation is required to 
understand the persistence of the AAV transgene and the need for additional 
supplementation of gene replacement in the long run. 
Our ablate-and-replace system has potential for other autosomal dominant 
diseases beyond retinitis pigmentosa. For example, Vitelliform Macular Dystrophy is a 
blinding macular disorder that may be caused by any one from more than 200 autosomal-
dominant point mutations in the gene BESTROPHIN 1 (BEST 1), which encodes a calcium-
dependent chloride channel168-170; Transthyretin amyloidoses is associated with 83 ad 
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mutations in the TTR gene171; and amyotrophic lateral sclerosis has more than 80 
mutations on the SOD1 gene172. Instead of mutation-specific targeting, our system 
















IV. FUTURE DIRECTIONS  
The current study provides evidence for the efficiency and feasibility of “ablate-
and-replace” therapeutic strategy on rodent adRP models. However, for the clinical 
application, more tests are necessary to evaluate this strategy with human sequence. A 
hRHO-humanized mouse will be an ideal platform to test new, hRHO-targeting gRNAs for 
CRISPRd and to test new hRHO gene replacement underwent a new round of codon-


















CHAPTER 5: MATERIAL AND METHODS (FIRST PART) 
Plasmids and AAV production 
All gRNAs used in this study were designed by Benchling (https://benchling.com/). 
When selecting gRNAs, only those with excellent off-targeting scores (i.e. >80) were 
considered. The two gRNAs, labeled as gRNA1 and gRNA2, with the highest on-targeting 
scores were chosen and tested for use in this study (gRNA1 sequence: 
ctgtctacgaagagcccgtg; gRNA2 sequence: cccacaggctgtaatctcga). For in vitro gRNA 
specificity test, gRNA1+gRNA2 or gRNA2 alone expressing cassettes were cloned into 
pX459 (Addgene), which encodes SpCas9. For the production of the AAV-GR, 
gRNA1+gRNA2-expressing cassettes and a 2.2 kb mRho promoter-driven hRHO cDNA-
expressing cassette were cloned into pZac2.1 vector (PL-C-PV0100, The Penn Vector Core, 
University of Pennsylvania). For the AAV-SR, gRNA sequences were replaced with scrambled 
sequences that do not exist in the mouse genome. For the AAV-Cas9, codon-optimized SpCas9 
was cloned into pZac2.1 between the sCMV promoter and SPA sequence. The AAV2/8 (Y733F) 
was generated by The Penn Vector Core, University of Pennsylvania. 
 
In vitro CRISPR digestion assay 
To validate the targeting efficiency of our system, gRNA (25 ng/μl) was added to 
the reaction mixture alongside Cas9 protein (30 ng/μl, NEB) and template mRho DNA (20 
ng/μl, 750 bp) covering both targeting sites of gRNA1 and gRNA2, and they were 
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subsequently incubated at 37° C for 2 hr. After Cas9/gRNA digestion, the mixture was 
analyzed by agarose gel electrophoresis.  
 
Animals 
Human mutation P23H knock-in and C57BL/6J mice were purchased from Jackson 
Labs to generate RhoP23H/+ and RhoP23H/P23H mice. Another human mutation knock-in 
model, D190N, was established as described before160. Animals were maintained on a 12-
h light-dark cycle. Before ERG, animals were anesthetized with a mixture of ketamine 
hydrochloride (10 mg/100 g; Ketaset®, Fort Dodge Animal Health, Fort Dodge, IA, USA) 
and xylazine (1 mg/100 g, Anased®; Lloyd Laboratory, Shenandoah, IA, USA). As per 
regulations of the Institutional Animal Care and Use Committee (IACUC), animals 
sacrificed for histology were euthanized by placement in a CO2 chamber for 3 min 
followed by cervical dislocation. All efforts were made to minimize the number of animals 
used and their suffering. All mouse experiments were approved by the IACUC and 
conform to regulatory standards. All mice were used in accordance with the Statement 
for the Use of Animals in Ophthalmic and Vision Research of the Association for Research 
in Vision and Ophthalmology, as well as the Policy for the Use of Animals in Neuroscience 







ERGs were performed at indicated time points as previously described160. Briefly, 
animals were dark-adapted overnight, and their pupils were dilated with 0.5% 
tropicamide and 2.5% phenylephrine. Animals were then anesthetized with ketamine, 
and ERG responses were obtained using pulses of 3 cd × s/m2 (white 6,500 K) light. ERG 
a- and b-wave magnitudes and maximal scotopic and photopic recordings were collected 
at P21 for RhoP23H/P23H, P40 for RhoP23H/+, and P90 for RhoD190N/+ mice. 
 
Subretinal injection 
AAV-Cas9 (1 x 1013 particles/ml) was premixed with AAV-GR or AAV-SR (1 x 1013 
particles/ml). Mice at age P1-P3 were anesthetized according to established IACUC 
guidelines, and subretinal injections were performed with a single injection of 1.5 μl. The 
injection was done from the posterior part of the eye. All mice included for analysis had 
ideal bleb detachments at the retinal site of the injection as judged by postsurgical fundus 
examination. Mice with complete retinal detachment confirmed by both postsurgical 







Genomic DNA extraction and genomic PCR 
Genomic DNA from retinae was extracted using the Blood & Tissue kit (QIAGEN). 
Genomic PCRs were performed using Phusion DNA ploymerase (Fisher Scientific). Primers 
for the detection of gene truncation and NHEJ were as follows: Forward: 
tacctaagggcctccacccg; Reverse: tttgccaatgaataagctggg. PCR amplicons generated from 
3T3 cell culture or gross retinal DNA samples were further subcloned by the TOPO-TA 
cloning kit (Invitrogen) and analyzed by Sanger sequencing. 
 
Cell culture and plasmid transfection 
Mouse fibroblast 3T3 cell line was purchased from ATCC. The mycoplasma 
contamination test was performed every month. The cells were seeded in a 6-well plate 
at 1 x 106 cells/well. When the cells reached 75% confluency, the pX459 plasmids (2.5μg) 
of CRISPRd or CRISPRs were transfected into 3T3 cells by Lipofectamine 2000 (Invitrogen). 
The cell culture was further purified by puromycin selection at 2μg/ml starting at 48 hours 
after transfection. DNA extraction was carried out after two weeks of selection. 
 
Immunostaining 
Mice were euthanized, and eyes were enucleated and placed in 4% 
paraformaldehyde for 1 h at room temperature. The optic nerve, cornea, and lens were 
removed. The whole eyecup was then flattened by means of four radial cuts extending 
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out from the optic nerve and mounted with mounting medium (Vectashield, Vector 
Laboratories). Anti-Cas9 primary antibody (1:200 Abcam ab191468) and secondary 
antibody-conjugated Alexa 488 (Invitrogen, A11017) staining were performed according 
to the manufacturer’s instruction. Visualization was achieved by fluorescence microscopy, 
and bright-field imaging was used to visualize the whole retina (Leica DM 5000B 




Mice were euthanized, and eyes were enucleated and fixed. H&E histology was 
carried out as previously described160. 
 
Real-time PCR and relative mRNA quantification 
Retinas were harvested at the indicated time and lysed with TRIZOL reagent 
(Invitrogen). Total RNA was isolated according to the manufacturer's instructions. DNase 
I (Invitrogen) treatment was then performed to prevent genomic DNA contamination. The 
reverse transcription reaction was conducted by Superscript III Reverse Transcription kit, 
and a random hexamer (Invitrogen) was used to generate cDNA. Real-time PCR method 
was performed using Maxima SYBR Green/ROX qPCR Master Mix (Fisher Scientific) with 
StepOne Real-time PCR System (Invitrogen) to quantify gene expression levels. The mRho 
and hRHO mRNA expression level was determined and normalized with the rod 
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photoreceptor cell housekeeping gene, Pde6g. The PCR products were validated by 
melting curve and agarose gel electrophoresis. The following primers were used: mRho 
forward: 5′- TGGGCCCACAGGCTGTAATCTC-3′; mRho reverse: 5′- 
GAAGACCACACCCATGATAGCGTGA-3′; hRHO forward: 5′- CTTTGCCAAGAGCGCCG-3′; 
hRHO reverse: 5′- AGCAGAGGCCTCATCGTCA-3′. Pde6g forward: 5′- 


















CHAPTER 6: ESTABLISHMENT OF GENE CORRECTION TOOLSET FOR DOYNE HONEY 
COMB DYSTROPHY 
I. INTRODUCTION  
Though many hypotheses have been proposed, it is still unclear how the 
EFEMP1R345W mutant protein can cause drusen formation and lead to the disease. With 
the fact that EFEMP1 is expressed exclusively by RPE cells in the retina, we hypothesize 
that the expression of EFEMP1R345W may change RPE physiology. Because of the onset of 
this disease is usually around 30’s to 40’s and drusen formation is a slow, progressive 
process, that cellular, physiological phenotype may be subtle. In order to precisely reflect 
the EFEMP1R345W -induced phenotype, we tended to create an isogenic cell line pair in 
which, the only difference is the single nucleotide mutation of EFEMP1R345W.  Since DHRD 
is a monogenic disease, we expect that this rigorous phenotyping clarify the consequence 
of mutant EFEMP1 expression in RPE cells. 
The R345W mutation is a C>T mutation on exon 10 of EFEMP1 gene. To create an 
isogenic cell line, we obtained DHRD patient fibroblast-derived iPSC cells. We expected to 
perform gene correction by CRISPR-induced homology directed repair. The yield iPSC 








II. RESULTS  
To create a double strand break at the EFEMP1 mutation site, we designed three 
different gRNAs to target the EFEMP1 mutation locus on exon 10 (Fig. 31). The design was 




Figure 31. gRNA targeting sites. Three gRNAs sg006, sg007 and sg008 (from top to 
bottom) targeting the EFEMP1R345W mutation were designed by Benchling. 
 
These three gRNAs, sg006, sg007 and sg008 were tested in vitro for targeting 
efficiency (Fig. 32). By mixing SpCas9 protein and each of these gRNA individually with 
wildtype or mutant templates, more digested fragments instead of parental band in the 
sg008 group was observed, indicating highest targeting efficiency among all gRNAs. 
However, we noticed that no one of the gRNA can specifically target the mutant sequence, 
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Figure 32. In vitro gRNA targeting. Three gRNAs sg006, sg007 and sg008 were used to 
challenge dsDNA fragment bearing wildtype or R345W mutation sequence. The 650bp 
band is the parental sequence of the uncut template. If cut, the parental band should be 
digested into two bands with size around 400bp and 250bp. 
 
To facilitate homology dependent repair (HDR) to happen, addition of donor 
template is necessary when inducing double strand break at the mutation site by 
Cas9/gRNA. We designed a 128bp single-stranded oligodeoxynucleotide (ssODN) (Fig. 33). 
Compared to the mutant sequence, this ssODN contains three mismatches: one to correct 
C>T mutation and the other two contributes to two silent mutations, which were set to 
allow colony screening by restriction fragment length polymorphism (RFLP). The mini 
homology arm on each side of this ssODN are 60bp long. The expected sequence after 




Figure 33. Donor template design. The donor template (ssODN) used to facilitate 
homology directed repair contains three different mismatches comparing to the 
EFEMP1R345W sequence. Despite one mismatches to correct the R345W mutation, the 
other two mismatches were created to enable restriction fragment length 




We chose Lonza nulceofector 4D to perform the transfection of Cas9/gRNA and 
donor template. To optimize the transfection efficiency of the patient iPSC, we tested 
different nucleofection protocols with different nucleofection reagents and conditions 



























Figure 34. Optimization of nucleofection program. The iPSC cells were mixed with 
plasmid pMAX-GFP in Amaxa solution P3 (first array) or P4 (second array). The 
nucleofection was carried out using programs CA-137, CM-138, CM-137, CM-150, DS-
150, DS-120, EH-100, EO-100, DN-100, DS-138, DS-137, DS-130, EN-138, EN150, EW-113 
























The iPS cells were treated with ROCK inhibitor to prevent apoptosis. Right before 
nucleofection, the iPSC was detached by accutase from the dish and dispersed into single 
cell suspension. The cells were then mixed with P3 or P4 buffer for nucleofection and put 
pmax-GFP at a ratio 0.5ul in each well of the strip. Each of the wells contains 2*10^5 cells. 
The cells were then nucleofected by CA-137, CM-138, CM-137, CM-150, DS-150, DS-120, 
EH-100, EO-100, DN-100, DS-138, DS-137, DS-130, EN-138, EN150, EW-113 and 
CB150 programs. The fluorescence and cell survivability were recorded on the next day. 
All the conditions gave low survival rate (Fig. 34). The intensity of green 
fluorescence of CM-138, DS-150 and DS-130 were higher than average. Based on the 
fluorescence intensity and the survival rate of the cells, we concluded DS-150 with P3 
reagent is the best condition for efficient nucleofection for our patient iPSC. 
For the gene correction of R345W mutation, the patient iPSC was mixed with 
SpCas9 protein 1ug, gRNA 300ng and ssODN 500pmol in Solution P3 reagent and then 
nucleofected by DS-150 program. The resulted cells were split into single colony and 
expanded for one week. The colonies were screened by RFLP assay. Positive colony were 
further confirmed by Sanger sequencing (Fig. 35). Gene-corrected colony without artifact 





Figure 35. Sequencing result of iPSC colonies after gene correction. The iPSC colonies 
after nucleofection were manually picked and expanded. Sanger sequencing was used 





Though it has been reported that mismatches with in the 3’ end region of gRNA 
can disable the targeting173, 174. However, in our study, even though the wildtype 
nucleotide cytosine is differ from that in the sg006, sg007 or sg008, all of these three still 
mediates the digestion of the wildtype template. This result may imply an unreliability of 
mutation-specific targeting by CRISPR based on single nucleotide difference. For many 
genetic diseases which only have single nucleotide mutation, using CRISPR to perform in 
vivo, gene ablation therapy may arise safety concerns, since the wildtype allele may be 
targeted as well. A CRISPR-based in vitro therapy combined with cell transplantation 


















CHAPTER 7: IPSC REPROGRAMING AND RPE DIFFERENTIATION  
I. INTRODUCTION  
For the precise phenotyping of EFEMP1R345W mutation, RPE cells will be the best 
cell model to study the physiological change. However, due to the limited availability of 
autopsy RPE cells and the difficulty of genetic manipulation on primary RPE cells, we chose 
to obtained RPE cells from DHRD patient iPSC. The possibility of in vitro differentiation of 
RPE from iPSC was first described in 2009175. In this study, the RPE cells were 


















DHRD patient skin biopsy was collected by a surgeon. This 5 mm skin biopsy was 
placed in culture dishes for two week to allow fibroblast to migrate to the cover slide. 
These fibroblast were propagated and transduced by Sendai viruses expressing OCT3/4, 
SOX2, cMYC and KLF4. The iPSC colonies formed in the cell culture were picked up for 
colonial expansion. The quality of these iPSC colonies were confirmed by immunostaining 
of iPSC markers TRA-1-60, SOX2, SSEA4 and OCT4 (Fig. 36 and 37).  
The nuclear expression of SOX2 and OCT4 was clearly detected, as well as the 
cytoplasmic expression of TRA-1-60 and SSEA4. The colony edge remained clear and clear 
indicating no sign of differentiation. 
 
 
Figure 36. Immunostaining of TRA-1-60 and SOX2. TRA-1-60 (green) and SOX2 (red) 




Figure 37. Immunostaining of SSEA4 and OCT4. SSEA4 (green) and OCT4 (red) were 
detected in iPSC culture.  
 
To differentiate iPSC colony into RPE cells, the iPSC were grown to 90% confluency 
before the treatment of nicotinamide. After differentiating in nicotinamide-containing 
medium for two weeks, the differentiating medium were further enriched by activin A for 
the next two weeks of culture. Sporadic, tiny black spots in the cell culture started to 
appear in the last week of incubation. 
These black, pigmented cell colonies were manually picked up and transferred to 

















After 100-200 days of culture, the cells became pigmented (Fig. 39). Hexagon 
shape morphology was observed under microscope. This morphology resembles what 
observed in primary RPE cell culture from autopsy78. 
These RPE cell were further characterized by immunostaining of RPE specific 
marker BEST1 (Fig. 40). 
 
 
Figure 40. Immunostaining of RPE marker. Anti-BEST1 (red) and DAPI (blue) were used 
to stain iPSC-derived RPE.  
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III. Discussion  
There have been different differentiation protocol published. The most recent 
version comprises many growth factors, including IGF, Noggin and bFGF in addition to 
nicotinamide and activin A176. The RPE derived from iPSC treated with this protocol is 
reported to appear in as little as 14 days of treatment. However, this protocol is not 
reproducible in our lab and the result is variable among different iPSC clones based on 
our lab’s experience. The current study followed a simplified but more reliable version 
published by Buchholz et al. in 2009177, which primarily depends on the incubation with 
merely nicotinamide and activin A. However, a fly in the ointment, this protocol requires 
4-6 weeks of incubation to see pigmented RPE cells in the cell culture. Nevertheless, both 
of the protocols requires a differentiation time over than three months to obtain mature 
RPE cells and each round of subculture/passaging requires another three months for re-









CHAPTER 8: PHENOTYPING OF PATIENT IPSC-DERIVED RPE 
I. INTRODUCTION  
There has been some proposed hypotheses toward RPE pathogenesis. 
Accumulation of misfolded EFEMP1 proteins within the endoplasmic reticulum (ER) may 
activate a signaling pathway termed the unfolded protein response (UPR). This response, 
which is conserved from yeast to mammals, leads to the stress-responsive gene 
expression to increase ER protein processing capacity and boost ability to degrade 
misfolded proteins aggregating within the ER178. UPR may induce the expression of VEGF, 
which is also discovered in DHRD and RPE179, 180.  
In addition to UPR, aberrant immune response has also been suggested to involve 
in the pathogenesis of AMD disease181, 182. NLRP3 inflammasome has been found to be 
upregulated in AMD patient RPE cells. This upregulation induced the release of 












ER stress/unfolded protein response (UPR) markers GRP78 (Bip) and XBP-1a as 
well as VEGF were reported to increase when overexpressing mutant EFEMP1 in ARPE19 
cell line53. To validate the involvement of UPR, we screened the UPR biomarkers, sXBP1, 
usXBP1, total XBP1, ATF4, CHOP, GRP778/Bip, GRP94, EDEM and VEGF expression using 
real-time PCR in the patient iPSC-derived RPE cells (Fig. 41). The cell clones were divided 
into three groups: Untreated mutant, gene corrected and wildtype control.  
 
 
Figure 41. Real-time analysis of unfolded protein response biomarkers. The patient 
iPSC-derived RPE cells from the three groups, wildtype, EFEMP1+/R345W mutant and gene 
corrected EFEMP1+/+ were analyzed for unfolded protein response biomarkers and VEGF 






Every group consists 5-8 clones of RPE derived from patient or healthy donors. We 
expected the expression of these markers to be low in the wildtype control group and 
high in the mutant group. Likewise, after gene correction the cell should behave similar 
to wildtype control, with low expression of UPR markers. However, we detected low 
expression of all markers in all the clones. The trends of each markers didn’t match the 
pattern we expected, either. We concluded that UPR is not as activated by mutant 
EFEMP1 expression. 
Next, we validated if mutant EFEMP1 can induce aberrant immune response in 
RPE cells or not. Since cytokine release is a common outcome of nearly all kinds of 
immune-related pathways (NLRP3 and NF-kB), we screened cytokine release of IL-1 and 
















Figure 42. ELISA analysis of pro-inflammatory cytokines. The supernatant form patient 




Surprisingly, no IL-1 or IL-18 was detected in all the screened clones (Fig. 42). All 
the cytokines level were very low in the supernatant, close to background. Only clone 1 
in the wildtype group has appreciable but little IL-18 expression. This wildtype donor was 
obtained from patient with URSHER syndrom, which does not share clinical similarity with 
AMD or DHRD. 
We abandoned existing hypotheses since those cannot explain what was observed 
in our disease model. We in turn, used untargeted mass-spectrophotometer to analyze 


























Figure 44. Volcano plot comparing proteomic profiles between patient and wildtype 
iPSC-derived PREs. A base-2 log scale is used for the abscissa (X axis), ranging from 







Figure 45. Volcano plot comparing proteomic profiles between gene-corrected and 
mutant iPSC-derived RPEs. A base-2 log scale is used for the abscissa (X axis), ranging 







By comparing the protein expression profiles, we found CES1 protein expression 
level is significantly decreased in patient RPE cells when compared to wildtype RPE cells 
(p< 1 x 10E-9) (Fig. 44). This findings is consistent between two DHRD patients. After using 
CRISPR to correct the R345W (C>T) mutation, the CES1 expression level is then restored 
(Fig. 45). We concluded CES1 expression level is affected by the mutant EFEMP1. 
Since CES1 has been reported to be a rate-limiting step of cholesterol efflux 
process, we further analyze the protein expression level related to cholesterol transport 
and catabolism. However, no significant change has been found in any transporter or 
catalytic enzyme, but only CES1 is affected (Fig. 46). 
 
 
Figure 46. Protein level changes after gene correction. Protein involved in lipid 







Though it has been reported over-expression of EFEMP1R345W in ARPE19 can lead 
to UPR53, in our experiment, we did not see any sign of UPR response in the patient RPE 
cells. Given that the patient iPSC-derived RPE is more authentic than the immortalized 
APRE-19 cell line, this result implies that the UPR detected in ARPE19 can be artifact 
resulted from excessive gene expression. Besides UPR, VEGF is elevated in RPE cell culture, 
according to Roybal et al.53, which is not detected in our disease model, either. Because 
VEGF is also a common target of UPR pathway shared with hypoxia factor, HIF-1 
signaling183, lacking of VEGF response also indirectly indicates the dormancy of UPR. 
Photo-oxidative stress184-186, lipid peroxidation187-189, Toll-like receptor190-192 and 
alternative complement pathways have been proposed to compose a sophisticated 
immunopathogenesis toward AMD. Induction of inflammation and release of pro-
inflammatory cytokines IL-1 and IL-18 is discovered to be a common consequence of these 
pathways. However, the absence of these cytokines in our RPE culture indicates that the 
way EFEMP1R345W causes disease is independent to these pathways. 
Excessive lipid droplet deposition in RPE cells has also been reported in both AMD 
patient RPE cells193 and iPSC-derived RPE cells from both AMD and DHRD patients193, 194, 
these findings strongly suggest dysregulation of lipid transport or catabolism in these 
disease. CES1 belongs to the carboxylesterase family of enzymes that was first identified 
in liver195, 196. CES1, with an alternative name as cholesterol ester hydrolase (CEH), is 
responsible for the mobilization of cholesteryl ester in macrophage197 (Fig. 47). 
Cholesteryl ester is the form of cholesterol for long-term storage in the cell. When input 
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from outside source, free cholesterol is converted to cholesteryl ester and stored in lipid 
droplets. This conversion is usually mediated by ACAT1 and ACAT2 enzymes (Fig. 47). In 
contrast, the efflux of cholesterol which requires the mobilization of cholesteryl ester. 
This conversion is mediated by a multiple enzyme process, in which CES1 is indispensable 
(Fig. 47).  
Though the role of CES1 has never been studied in RPE cells, it has been suggested 
to participate in the efflux of cholesterol in foam cells during the regression phase 





Figure 47. Hypothesis illustration of potential mechanism resulting intracellular lipid 
accumulation.  
The accumulation of lipid in RPE can be possibly due to increased influx and 
decreased efflux of cholesterol. However, in our study no transporter protein or influx 
protein was affected by gene correction of EFEMP1R345W mutation, indicating the efflux 




















IV. FUTURE DIRECTIONS 
Though the data from current study reveal the involvement of CES1 in the disease 
development, it is not clear how EFEMP1R345W mutant protein can affect the expression 
level of CES1. EFEMP1 is an extracellular matrix protein and does not participate in gene 
transcription. Given that the two genes reside in different chromosomes (Chr 2 and 16), 
intergenic interaction between two genes is not likely to be the correct explanation.  
However, further investigation is needed to determine whether the reduction of 
CES1 is resulted from increased degradation or decreased production that may be 













CHAPTER 9: MATERIAL AND METHODS (SECOND PART) 
Design of the gRNA and donor template  
All gRNAs used in this study were designed by Benchling (https://benchling.com/). 
When selecting gRNAs, only those covering the C>T mutation were considered. Three 
gRNAs, labeled as sg006, sg007 and sg008 with sequence 5’- gctgggaggatgaaatgtgt -3’, 5’- 
gaccacaaatgaatgctggg -3’ and 5’- tgagaccacaaatgaatgct -3’ were selected for in vitro 
testing. For gene correction of EFEMP1R345W mutation, donor template with sequence 5’- 
tagttagtaaactctttgaccctacatctctacagatataaatgagtgtgagaccacaaaCgaGtgcCgggaggatgaaatg
tgttggaattatcatggcggcttccgttgttatccacgaaatcctt was added when performing CRISPR. In 
total three nucleotides are different from the mutant sequence. Despite the cytosine at 
the mutated nucleotide, another cytosine and guanine (upper case) were created by 
silent mutations were included to enable colony screening by restriction fragment length 
polymorphism after nucleofection. The homology arms on each side is 60-mer long. 
 
In vitro CRISPR digestion assay 
To validate the targeting efficiency of our system, gRNA (25 ng/μl) was added to 
the reaction mixture alongside Cas9 protein (30 ng/μl, NEB) and template EFEMP1R345W 
DNA (20 ng/μl, 750 bp) covering all three targeting sites of sg006, sg007 and sg008. The 
mixture was subsequently incubated at 37° C for 2 hr. After Cas9/gRNA digestion, the 




Genomic DNA extraction and genomic PCR 
Genomic DNA from retinae was extracted using the Blood & Tissue kit (QIAGEN). 
Genomic PCRs were performed using Phusion DNA ploymerase (Fisher Scientific). Primers 
for the detection of gene truncation and NHEJ were as follows: Forward: 5’- 
ttttgctggccttttgctcac -3’; Reverse: 5’- acatttccccgaaaagtgcca -3’. PCR amplicons generated 
from iPSC cell culture or gross retinal DNA samples were further subcloned by the TOPO-
TA cloning kit (Invitrogen) and analyzed by Sanger sequencing. 
 
Cell culture and nucleofection 
Patient fibroblasts were transduced by sendai vectors to create iPS cell lines 
according to previously established protocols199-201. The methods used to induce 
undifferentiated iPS cells to differentiate into RPE-like cells have been described in 
detail177. In brief, iPS cells cultured on matrigel were transduced with viral vectors carrying 
transcription factors OCT4, SOX2, KLF4 and MYC. The cells were further incubated in 
mTeSR medium under 5% CO2 at 37°C. To perform CRISPR-mediated gene correction, 1 x 
106 cells, SpCas9 protein 5μg (2.5μl), gRNA 1500ng (1μl) and ssODN 1000pmol (2μl) were 
mixed with Amaxa solution P3 to a final volume at 20 μl. After incubation at room 
temperature for 10 mins, the cells were nucleofected using Lonza 4D nucleofector by 
DS150 program. After the nucleofection, the cells were immediately transferred to 6 cm 
dishes. After 48 hours of incubation, the cells were transferred to 10 cm dish for colony 
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picking. Restriction fragment length polymorphism with ScrFI was used to screen the 
positively gene-corrected clones. For the differentiation of iPSC cells into RPE, iPSC cells 
were grown to 90% confluency. For the first phase of differentiation, the cells were put in 
medium with 100 mM Nicotinamide in DMEM for 14 days. In the second phase, cells were 
treated with medium contains additional 100 ng/ml activin A for another 14 days before 
turning back to phase I medium. The pigmented spots in cell culture, which contains RPE 
cells, were transferred in to another culture plate. The cells were then propagated and 
enriched in RPE medium which contains N1 supplement and THT202. 
 
Figure 48. Medium and components used for RPE differentiation. 
 
Immunostaining 
Four antibodies against pluripotency markers (TRA-1-60, SSEA4, NANOG and SOX2 
[ASK-306, Applied StemCell, Menlo Park, CA, USA]) were used to characterize the iPSC 
reprogrammed from the patient fibroblasts. Secondary antibodies conjugated Alexa Fluor 
488 goat anti-rabbit or Alexa Fluor 555 goat anti-mouse IgG (1:1,000; Invitrogen; Life 
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Technologies). For the characterization of RPE cells, anti-BEST1 primary antibody was 
used. DAPI (4′,6-diamidino-2-phenylindole) was used to stain nuclei. Images for all 
antibody labels were taken under the same settings with a fluorescence microscope (Leica 
DM 5000 B).  
 
Mass spectrophotometry  
For the sample preparation, each cell pellet was homogenized with 1% NP-40 lysis 
buffer with protease and phosphatase cocktails. Enhanced BCA Protein Quantification 
assay was used to determine the total protein amount of each sample. Proteins from 50 
μg of serum filtrate were purified by mini S-trap columns (http://www.protifi.com/s-trap/) 
and digested on column by trypsin. The Thermo Quantitative Fluorometric Peptide Assay 
was used to quantify peptide concentrations prior to TMT labeling. 40μg peptides were 
labeled with TMT 6plex isobaric reagent and mixed for high pH reverse phase peptide 
fractionation. Thermo Orbitrap Fusion Tribrid Mass Spectrometer was used for MS/MS 
analysis  (MS3 data acquisition method). Technical replications were run according to the 
table on the right. Each set was run in triplicates. Proteome Discoverer software (version 
PD 2.1) was used to search the acquired MS/MS data against human protein database 
downloaded from the UniProt website and generate TMT ratios. Positive identification 
was set at 5% peptide FDR. Also, at least 1 unique peptide has to be identified per protein. 
Duplicated protein identifications from database were removed. Total of 4605 human 
proteins were quantified and included in the final data. TMT ratios (each tag/common 
reference) were calculated by PD 2.1 and normalized by total peptide amount. Qlucore 
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Omics Explorer & Prism 6 Software were used to perform correlation and statistical 
analysis. KNN imputation was used for missing values.     
 
Real-time PCR and relative mRNA quantification 
RPE cells were harvested at the indicated time and lysed with TRIZOL reagent 
(Invitrogen). Total RNA was isolated according to the manufacturer's instructions. DNase 
I (Invitrogen) treatment was then performed to prevent genomic DNA contamination. The 
reverse transcription reaction was conducted by Superscript III Reverse Transcription kit, 
and a random hexamer (Invitrogen) was used to generate cDNA. Real-time PCR method 
was performed using Maxima SYBR Green/ROX qPCR Master Mix (Fisher Scientific) with 
StepOne Real-time PCR System (Invitrogen) to quantify gene expression levels. The 
expression level of unfolded protein response biomarkers were determined and 
normalized with actin. The PCR products were validated by melting curve and agarose gel 









Figure 49. Primers list for real-time PCR. 
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